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ABSTRACT 
Background: Cutaneous scarring is a reparative response to wounding in an attempt to 
restore homeostasis. Pathologic scars include hypertrophic and keloidal scars. No defined 
dermal scar fibroblast phenotype has been described. This study examines for such a 
phenotype, looking at expression patterns and spatial relationships of CD90, CD34 and 
smooth muscle actin (SMA) expressing fibroblasts in cutaneous scars. Additionally, this 
work investigates for evidence of scar fibroblast transition from the background CD34
+
 
stromal cell network. It also delineates a timeline for the appearance/disappearance of 
this phenotype in physiologic scarring. Finally, it assesses the relative contributions of 
CD90
+
 and SMA
+
 fibroblasts to scar collagenization. 
Methods: 117 scars were classified as reparative (n=47), hypertrophic (n= 40) or keloidal 
(n=30). Where possible, scar age was calculated. Immunohistochemistry with CD90, 
CD34 and SMA was performed on all scars. Double-staining immunohistochemistry for 
CD90/CD34 was applied to all scars assessing for the presence of dual CD90
+
/CD34
+
 
transitioning cells. Double-color immunofluorescence was also performed to further 
  x 
identify transition. A subset of scars was double stained with CD90/SMA to evaluate 
spatial relationships. Additional scars were double-stained with CD90/procollagen-1 or 
SMA/procollagen-1 to assess for active collagen synthesis. Expression was graded as 
diffuse, focal/rare (i.e. minority) and negative.  
Results: A CD90
diffuse
/CD34
negative/minority 
pattern was the most commonly observed 
phenotype among all scars. SMA expression was variable. Transitioning CD90
+
/CD34
+
 
fibroblasts were observed in 90.6% of scars. In reparative scars, a 
CD90
diffuse
/CD34
negative/minority
 phenotype was time-limited, developing within 48 hours 
and reverting to a CD34
diffuse
 state at 160–180 days. Many pathologic scars exhibited 
prolonged CD90
diffuse
 expression. Both CD90
+ 
fibroblasts and myofibroblasts express 
procollagen-1. CD90
+ 
fibroblasts contributed more cells to scar mass than 
myofibroblasts. When spatial relationships were examined, myofibroblasts exclusively 
localized to CD90
+
 areas and exhibited CD90 double-positivity. CD90 expression was 
not limited to SMA
+ 
zones. 
Conclusions: Scar fibroblasts predominantly exhibit a CD90
diffuse
/CD34
negative/minority 
phenotype. These CD90
+
 fibroblasts likely transition from the background CD34
+
 
network. This phenotype is reversible in reparative scars, but is prolonged in some 
pathologic scars. Both CD90
+
 fibroblasts and myofibroblasts collagenize scars. The co-
localization of myofibroblasts to CD90-rich areas and CD90 dual-positivity may suggest 
a common origin.  
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CHAPTER 1: INTRODUCTION 
 
Cutaneous scarring is a reparative fibrotic response of the skin to wounding, with the aim 
to restore barrier integrity and homeostatic functionality. While simple reparative 
scarring differs from true regeneration in its imperfect reproduction of texture, color, 
elasticity and depending on the depth and extent of injury, cutaneous adnexae, it is a 
physiologic rather than pathologic process which most frequently results in adequate 
restoration of function, and often acceptable aesthetic results. As with all normal 
reparative processes however, an excessive or inadequate response leads to aberrant 
outcomes. In skin repair an excessive scarring response results in the development of a 
pathologic scar. The two main types of pathologic scars are hypertrophic and keloidal 
scars (keloids) which differ from simple reparative scars in their bulky clinical 
appearance, prolonged course and histopathological features.  
 
Despite extensive and important work done in the field of wound healing, a 
comprehensive understanding of the complex nature of skin repair is lacking and while 
well-established phases of wound healing have been elucidated, aspects of the cellular 
and molecular biology/pathology of cutaneous restoration and aberrant scarring remain 
unknown. One such information-gap is the absence of a well-defined dermal “wound-
healing” fibroblast phenotype beyond the traditional smooth muscle actin (SMA) 
expressing myofibroblast. As will be discussed in the literature review, recent work in 
various organ systems, including the skin, point to the existence of a population of 
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fibroblasts expressing the glycosylphosphatidylinositol (GPI) anchored protein CD90 
(Thy-1). While the exact role of these cells in fibrotic disease seems to vary among organ 
systems, there is mounting evidence that in the skin, they are associated with a pro-
fibrotic state, though specific work regarding their contribution of cutaneous scarring has 
yet to be undertaken. Additionally, while scar fibroblast origin has been studied in other 
organ systems, data regarding their origin in cutaneous fibrosis is incomplete and 
inconclusive. In this regard, only rare investigators have given attention to the role of the 
quiescent background CD34
+
 fibroblastic stromal cell network consistently present in 
normal skin, as a resident source for wound healing fibroblasts. 
 
In an attempt to delineate a scar fibroblast phenotype, this study examines the changes in 
fibroblast protein expression phenotypes among all three categories of cutaneous scars 
and compares these patterns with uninjured skin and between each scar type. Specifically, 
it investigates for the presence of a CD90
+
 fibroblast population, looks for evidence 
suggestive of local transition from the background CD34
+
 reticular network, assesses for 
variations in protein expression patterns and attempts to elucidate the natural history of 
CD90 and CD34 expression in scars, by demonstrating a timeline for their 
commencement and disappearance in reparative scar fibroblasts. Also addressed is the 
relationship, if any, between these fibroblasts and classical SMA
+ 
myofibroblasts, the 
currently lauded main-player in fibrotic disease. 
  
Chapter two highlights the background clinical and pathologic basis for defining scars as 
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simple reparative versus pathologic and briefly reviews the relevant literature related to 
fibroblast expression of the evaluated proteins with respect to wound healing and fibrosis. 
Chapter three outlines the hypotheses to be tested and proposes a hypothetical model of 
reparative scarring predicted from existing data and investigator driven postulation while 
chapter four will review the relevant materials and the study methodology. Results and 
the discussion of their interpretation and relevance will be presented in chapters five and 
six respectively with chapter seven discussing limitations and the final chapter will 
summarize the overarching themes explicated herein. 
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CHAPTER TWO: BACKGROUND AND REVIEW OF THE LITERATURE 
 
2.1 Wound healing and physiologic scarring 
 
Cutaneous scarring is an extra-uterine physiologic fibrotic response to wounding. Unlike 
early gestational age fetuses, children and adults with dermal injury heal with some 
degree of fibrosis (Rowlatt, 1979). Fibrosis is an attempt to return the damaged dermis to 
its pre-wound state and while significant variation in cicatrix quality exists, the vast 
majority of injuries heal without significant functional or devastating aesthetic 
complications. These simple reparative scars are often asymptomatic and are 
characterized by a flat appearance and time dependent diminishing of erythema and other 
signs of inflammation. The adjacent uninjured skin typically does not exhibit abnormal 
texture, color or changes in elasticity as the reparative process is largely limited to the 
specific area of injury. These scars are the product of successful and well regulated 
(though partially overlapping) stages of wound healing, classically divided into 
inflammatory, proliferative and remodeling/maturation phases, which are briefly 
reviewed (Figure 1).   
 
The inflammatory stage occurs immediately after wounding and begins with the 
formation of the platelet plug. In addition to its hemostatic properties, the platelet plug is 
a key source of cytokines, in particular, platelet derived growth factor (PDGF) and to a 
lesser degree transforming growth factor beta (TGF-β). Release of these cytokines results 
in the influx of inflammatory cells (initially neutrophils and later 
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monocytes/macrophages) as well as the activation of quiescent resident fibroblasts 
(Childs & Murthy, 2017; Goldman, 2004). Along with an antimicrobial function, the 
inflammatory cells themselves function as a source of numerous cytokines and growth 
factors including vascular endothelial growth factor (VEGF) and transforming growth 
factor beta (TGF-β), important for angiogenesis, fibroblastic differentiation and transition 
to the proliferative phase (Gurtner, Werner, Barrandon, & Longaker, 2008). 
 
The proliferative phase begins at around 48 hours and is characterized by keratinocyte 
migration, vascular proliferation and later by fibroblast production of new extracellular 
matrix (ECM) composed primarily of collagen. Important for wound contracture is the 
conversion of fibroblasts to contractile myofibroblasts, primarily under the influence of 
TGF-β and in response to increasing ECM tension (Gurtner et al., 2008; Werner, Krieg, 
& Smola, 2007). This phase correlates histologically to granulation tissue (early 
proliferation) and the characteristic cellular scar (established proliferation).  
 
The remodeling phase begins at approximately 2 weeks, lasting up to 12 months. It is 
characterized by a delicate balance between fibroblast/myofibroblast production of the 
ECM and its breakdown by proteolytic enzymes, particularly matrix metalloproteinases 
(Nwomeh, Liang, Diegelmann, Cohen, & Yager, 1998). As the ECM returns to its pre-
wound tension, activated fibroblasts/myofibroblasts disappear from the wound 
(classically thought to be achieved via apoptosis) and this phase histologically correlates 
with the relatively acellular “aged” scar. 
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Figure 1. Phases of wound healing 
  
 
Inflammatory Phase 
 
1. Wounding leads to 
development of the platelet 
plug 
 
2. Release of cytokines including 
PDGF attracts inflammatory 
cells to wound 
 
3. Inflammatory cells and 
activated  
keratinocytes release 
additional cytokines including 
VEGF and TGF-β, with TGF-
β activating quiescent 
fibroblasts 
 
Proliferative Phase 
 
1. Under the influence of VEG-F, 
angiogenesis occurs 
contributing the vascular 
component of granulation 
tissue 
 
2. TGF-β and increasing ECM 
tension initiate 
myofibroblastic differentiation 
with expression of SMA 
 
3. Fibroblasts put down ECM 
primarily as collagen. Re-
epithelialization is also 
occurring at this time (dark 
blue arrowheads) 
 
Remodeling/Maturation Phase 
 
 Low-cellularity scar with 
parallel collagen bundles and 
vertically oriented blood 
vessels.  
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2.2 Pathologic scarring: hypertrophic scars and keloids 
 
Hypertrophic scars and keloids are similar but separate clinical entities characterized by 
an elevated and bulky clinical appearance. The primary clinical difference between these 
lesions is their relationship to the scar-line of the initial wound. Hypertrophic scars 
remain confined within the margins of the initial injury, while the expansile keloid 
extends beyond this margin. Additional clinical differences are highlighted in Table 1.  
 
Traditionally, histolopathologic differences between hypertrophic scars and keloids also 
exist (Table 1). Hypertrophic scars are composed of well circumscribed nodules and 
fascicles of plump fibroblasts with excessive but thin fibrillary collagen and rare to 
absent formation of thick glassy haphazard collagen bundles (keloidal collagen). 
Alternatively, keloids are defined by the presence of well-developed keloidal collagen, 
often with poorly defined borders, and in mature lesions, broad pauci-cellular areas with 
scattered, large fibroblasts. Histopathologic overlap however is commonly encountered in 
routine practice, and in conjunction with equivocal clinical data (“hypertrophic scar 
versus keloid”), may render precise scar classification difficult. In keeping with this, 
there exists a body of literature suggesting that these scars are not distinct entities but 
rather, are different manifestations of the same disease based on the overlapping clinical, 
histopathologic and proposed cellular/molecular pathophysiology (Atiyeh, Costagliola, & 
Hayek, 2005; Huang, Akashai, Hyakusoku, & Ogawa, 2014; Kose & Waseem, 2008; 
Lee, Yang, Chao, & Wong, 2004).  
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While the pathophysiology of hypertrophic scars and keloids is incompletely understood 
(Figure 2), a failure of the normal regulation of wound healing leading to an exaggerated 
response is likely, though the specific predisposing factors and molecular milieu which 
determines which pathologic scar variant will manifest are unclear. Specific 
abnormalities in the remodeling phase leading to an imbalance between ECM production 
and removal has long been proposed as a mechanism for bulky scar formation. Decreased 
expression and activity of the collagenase MMP-1 in keloids and hypertrophic scars has 
observed, though counter-intuitively, increases in MMP-2 in pathologic scars has also 
been demonstrated (Imaizumi et al., 2009; Lee, Trowbridge, Ayoub, & Agrawal, 2015).  
Additional reported differences in the extracellular matrix of hypertrophic scars and 
keloids include a preponderance of immature type III collagen in the former and a 
haphazard mixture of types I and III collagen in the latter (Bailey et al., 1975; Mari et al., 
2016).  
 
While wound healing phase-specific pathology may occur, evidence exists that 
pathologic scar fibroblasts may be intrinsically different from normal dermal fibroblasts 
and are therefore pathological in all phases of wound repair (Ashcroft, Syed, & Bayat, 
2013; Kischer et al., 1989; Suarez, Syed, Alonso-Rasgado, & Bayat, 2015). In this 
regard, an emerging hypothesis is that a failure of fibroblast apoptosis leads to the 
prolonged presence of ECM producing cells, accounting for the characteristic excessive 
collagen production. Suggested pathomechanisms for both hypertrophic scars and keloids 
include down regulation of pro-apoptosis-related genes, p53 mutations, resistance to fas-
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mediated apoptosis and elevations in the expression of the anti-apoptotic protein bcl-2 
(Linge et al., 2005; Lu, Gao, Ogawa, Hyakusoku, & Ou, 2007; Moulin et al., 2004; Saed 
et al., 1998).  
 
Differences in the cellular components of hypertrophic scars and keloids have largely 
focused on defining the presence or absence of myofibroblasts, with inconsistent results. 
While multiple studies highlight the increased number myofibroblasts in hypertrophic 
scars compared with keloids, others report significant positivity in the latter (Ehrlich et 
al., 1994; Lee & Vijayasingam, 1995; Lee et al., 2004). From a clinical perspective 
however, it is conceivable that keloids should have lower numbers of contractile 
myofibroblasts, since ineffective contracture intuitively seems pathomechanistically 
plausible in these expansile scars.  
 
An important advancement in the current pathophysiologic models of fibrosis is the focus 
on pro-fibrotic cytokine/growth factor signaling pathways. It is likely that an excessive 
pro-inflammatory/pro-fibrotic cytokine milieu plays an important role in the development 
of a pathologic scar (Armour, Scott, & Tredget, 2007). While numerous cytokines/growth 
factors are proposed to contribute to the development of hypertrophic scars/keloids, 
transforming growth factor beta (TGF-β) is the best studied and is reviewed below 
(Figure 3).  
 
TGF-β has 3 isoforms and of these, β1 and β2 appear to be profibrotic while the β3 isoform 
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signaling may result in diminished scarring (Finnson, Arany, & Philip, 2013). TGF-β is 
produced by a number of cell types including keratinocytes, macrophages and fibroblasts 
themselves. Intracellular TGF-β is synthesized as an inactive form and is subsequently 
bound to the TGF-β latency associated peptide (LAP) becoming the small latent complex 
(SLC). The SLC is cleaved and becomes covalently bound to latent TGF-β binding 
protein (LTBP) forming the large latent complex (LLC). Once secreted into the 
extracellular space, the LLC interacts with components of the extracellular matrix and 
microfibrils. Proteolysis leads to the LLC becoming solubilized. Soluble LLC can attach 
to target cell surfaces via interaction of LAP with integrins. Protease cleavage or 
conformational change based on αvβ6 integrin binding of LAP releases free/active TGF-β 
allowing for receptor binding and activation of downstream intracellular Smad proteins 
which enter the nucleus and induce transcription of profibrotic sequences (Biernacka, 
Dobaczewski, & Frangogiannis, 2011; Finnson, McLean, Di Guglielmo, & Philip, 2013; 
Ten Dijke & Arthur, 2007). Secretion and activation TGF-β is essential for normal 
wound healing, though excessive or prolonged expression leads to fibrosis. TGF-β 
secretion increases production of ECM components including fibronectin and collagens 
while inhibiting MMPs and increasing expression of MMP inhibitor proteins (Barrientos, 
Stojadinovic, Golinko, Brem, & Tomic-Canic, 2008). Additionally, TGF-β is a potent 
inducer in fibroblasts of a myofibroblastic phenotype important for normal scar 
contraction but also postulated to be a major source of the excessive ECM production and  
abnormal remodeling typical of multiple fibrosing diseases including pulmonary, hepatic 
and renal fibrotic disease (Hinz et al., 2012). Numerous reports highlighting an increased 
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expression of TGF-β and/or its receptors in fibroblasts from hypertrophic scars and 
keloids have be published, providing further evidence for its role in cutaneous fibrosing 
diseases (Bettinger, Yager, Diegelmann, & Cohen, 1996; Finnson, McLean, et al., 2013; 
Fujiwara, Muragaki, & Ooshima, 2005; Lee et al., 1999; Schmid, Itin, Cherry, Bi, & Cox, 
1998; Wang et al., 2000).  
 
 
Figure 2. A summary of the proposed pathomechanistic pathways for pathologic 
scar formation 
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Clinical & 
histopathologic 
features 
Hypertrophic scar Keloidal scar 
Racial 
predisposition 
None  Patients of African 
ancestry(Kelly, 1988)  
Area of 
predilection 
High skin tension High skin tension and low skin 
tension (earlobes) 
Pre-existing injury Almost always Sometimes though spontaneous 
lesions occur(Jfri, Rajeh, & 
Karkashan, 2015)  
Onset Immediately after injury Often insidious  
Pain/erythema Often Often 
Relationship to 
index wound 
margin 
Confined to index wound 
margin 
If injury associated, extends 
beyond wound margin 
Spontaneous 
resolution 
Occasionally  Unusual 
Conventional 
histology 
o Well defined fascicles 
or nodules of plump 
fibroblasts 
o Fibrillary collagen with 
little keloidal collagen 
o SMA rich nodules 
o Poorly defined margins 
o Abundant glassy keloidal 
collagen 
o Lack SMA rich nodules 
(Ehrlich et al., 1994) 
 
Table 1. Comparison of the clinical and histologic features of hypertrophic scars 
and keloids 
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Figure 3. Transforming growth factor beta signaling [1] Inactive intracellular TGF-β 
binds to LAP (SLC), and later [2] is covalently attached to LTBP (LLC), with subsequent 
secretion into the extracellular space. [3] Extra cellular LLC binds to the ECM at its N-
terminal and with microfibrils at the C-terminal. [4] Proteolytic cleavage of LTBP allows 
for solubilization of the LLC. [5] Soluble LLC attaches to its target cell via integrin 
binding and [6] further proteolytic cleavage of LAP or integrin associated conformational 
changes, results in release of active TGF-β. [7] Active TGF-β binds to its receptor and via 
SMAD signaling, induces [8] transcription of profibrotic sequences. SLC, small latent 
complex; LLC large latent complex 
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2.3 Regarding the origin of scar fibroblasts  
 
Multiple theories have been put forward to explain the origin of the scar fibroblast. Some 
of the major theories include activation of quiescent resident progenitor cells (reviewed 
below), transformation of circulating CD34
+
 hematopoietic “fibrocytes” to tissue 
fibroblasts and epithelial/endothelial mesenchymal transition (EpMT/EnMT) (Bucala, 
Spiegel, Chesney, Hogan, & Cerami, 1994; Kuwahara et al., 2016; Nazari et al., 2016).  
 
Activation of quiescent resident mesenchymal/stromal cells represents the classical view 
of scar fibroblast origin. Evidence exists that resident stromal/mesenchymal cells act as a 
source of active fibroblasts/myofibroblasts in various organ systems including the liver, 
kidney, lung and the heart (Furtado, Costa, & Rosenthal, 2016; Iwaisako, Brenner, & 
Kisseleva, 2012; Picard, Baum, Vogetseder, Kaissling, & Le Hir, 2008; Xia et al., 2014). 
Interestingly, despite the long acknowledged existence of a background CD34
+
 stromal 
cell network in skin, little attention has been paid to its role as a potential source of scar 
fibroblasts in cutaneous fibrosis.  
 
In the skin, a population of CD34
+
 fibroblastic cells are present in the dermal stroma as 
well as in a periappendegeal and perivascular location (Ceafalan, Gherghiceanu, Popescu, 
& Simionescu, 2012; Díaz-Flores et al., 2015). Various names have been attributed to 
these cells including telocytes, stromal fibroblastic cells, fibrocytic cells and dendrocytes 
among others (Díaz-Flores et al., 2014).  To avoid confusing terminology, we will use the 
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term CD34
+
 fibroblastic stromal cells/network. Ultrastructurally, these cells are 
characterized by a small triangular cell body and numerous long cytoplasmic processes, 
termed telopodes, which are involved in frequent cell-cell interactions with neighboring 
telopodes as well as other cell types, accounting for the extensive and intricate network 
noted with immunohistochemical staining for CD34 as viewed in a two-dimensional 
plane on standard histologic sections (Manole & Simionescu, 2016). While their biologic 
function is not completely understood, in the physiologic state, these low-proliferative 
capacity cells are proposed to contribute to architectural homeostasis, to have a role in 
vascular biology, to act as nurse cells for mesenchymal stem cells and importantly serve 
as a mesenchymal progenitor cell reservoir (Ceafalan et al., 2012; Díaz-Flores et al., 
2015). Supporting this latter concept is the observed presumed transition of activated gut 
CD34
+
 fibroblastic stromal cells to myofibroblasts in granulation intestinal tissue, with 
concurrent loss of CD34 expression (Díaz-Flores et al., 2015). While the majority of this 
work has been performed in extracutaneous tissue, a recent study presented evidence that 
in the fibrosing cutaneous disease scleroderma, pathologic CD90
+
 fibroblasts (see below) 
are derived from the background CD34
+ 
fibroblastic stromal cell network. In addition to 
loss of CD34 and neoexpression of CD90, dual positive fibroblasts expressing both CD34 
and CD90 were observed with a double-stain immunohistochemistry protocol and via 
immunofluorescence studies. These cells were interpreted as disease associated 
fibroblasts caught in transition and the authors suggested a reciprocal pattern of 
expression for these markers, with cells at the transitional poles being either 
CD34
+
/CD90
-
 or CD90
+
/CD34
-
 (Nazari et al., 2016). This finding is of paramount 
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importance to the genesis of this study’s hypotheses. Assuming potential analogy of 
fibrosis pathways in scleroderma and cutaneous scarring, we propose that evidence of 
this stromal → mesenchymal transition should also be found in dermal scars and if 
present, is compatible with a mesenchymal progenitor function of the CD34
+
 fibroblastic 
stromal cell network and specifically, supports the hypothesis that this network is a 
significant (and possibly the foremost) source of wound healing/scar fibroblasts in the 
skin.  
 
2.5 The CD90 (Thy-1) expressing fibroblast: what do we know? 
 
While determination of fibroblast origin is an important step adding to a more 
comprehensive understanding of cutaneous scar physiology/pathophysiology, of 
additional importance is the delineation of a reproducible cutaneous scar fibroblast 
phenotype. The CD90 expressing fibroblast has recently been described as playing 
various roles in fibrotic conditions involving different organ systems. These fibroblasts 
are typically not found in the quiescent dermis with the exception being in the 
perivascular and periadnexal adventitia (Nazari et al., 2016). While their role in skin 
disease is largely unexplored, the aforementioned research indicates that CD90 
expressing fibroblasts are present in cutaneous sclerosing diseases such as scleroderma. 
Additionally, they observed the presence of these cells in  benign fibrohistiocytic tumors 
and in a subset of scars (Nazari et al., 2016). CD90 is a glycosylphosphatidylinositol 
(GPI) anchored cell surface protein of the immunoglobulin superfamily (Williams & 
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Gagnon, 1982). Although no one clear biologic function has been elucidated, it is 
postulated to activate a number of signaling pathways, though given its cell surface 
location without an intracytoplasmic tail, how it does so is currently unexplained. With 
respect to scar formation, CD90 has been shown to activate TGF-β signaling an important 
pathway in fibrogenesis (Figure 3) (Rege & Hagood, 2006). Curiously, CD90 expressing 
fibroblasts may have different roles relating to fibrosis depending on the tissue involved. 
To this point, a CD90
+
 phenotype appears to be pro-fibrotic in the orbit (Grave’s 
ophthalmopathy), kidney (renal tubulointerstitial fibrosis) and in cardiac fibrosis, but 
protective against fibrosis in the lung (interstitial pulmonary fibrosis) (Brandau et al., 
2015; Hagood et al., 2005; Hudon-David, Bouzeghrane, Couture, & Thibault, 2007; 
Yuasa et al., 2013). It is also noteworthy, that baseline fibroblast CD90 expression varies 
among organ systems with unperturbed dermal stromal fibroblasts being CD90
-
 while a 
CD90
+
 phenotype is observed in the majority resident resting lung fibroblasts and a 
mixture of CD90
+/- 
cells in present the myometrium and kidney (Hagood et al., 2005; 
Koumas, King, Critchley, Kelly, & Phipps, 2001; Rege & Hagood, 2006). These data 
support the growing notion of tissue specific cellular functioning, where cells (in this case 
fibroblasts) exhibiting overlapping protein expression phenotypes have varying biologic 
roles dependent on the tissue of origin (Slany et al., 2014). It also underscores the 
importance of studying fibroblast biology in the tissue of interest, as extrapolation of 
results from experiments performed in other organ systems may yield incorrect 
conclusions.  
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When the function of CD90 was specifically examined in dermal fibroblasts with regards 
to its role in fibroblast proliferation and regulation of apoptosis, CD90 expression was 
associated with less fibroblast proliferation and more apoptosis compared to fibroblasts 
from CD90
-/- 
knockout mice suggesting an important role in regulation of fibroblast 
growth and homeostasis (Schmidt et al., 2015). The authors additionally examined for the 
effect of CD90 expression on fibroblast differentiation and function, demonstrating that 
CD90 expression was associated with significantly increased levels of bioactive TGF-β 
and mRNA expression of α-SMA, the extra domain A splice variant of fibronectin (ED-A 
FN), collagen I (α1) and collagen III (α1). Interestingly, when fibroblasts from CD90-/- 
knockout mice were seeded on immobilized, recombinant Thy-1 coupled to an IgG Fc for 
72 hours, a significant decrease in proliferation, and increased mRNA expression of α-
SMA, ED-A splice variant of fibronectin, collagen I (α1) and levels of bioactive TGF-β 
were observed (Schmidt et al., 2015). These results convincingly suggest that in skin 
fibroblasts, CD90 is actively involved in ECM production (specifically the laying down 
of collagen and ED-A FN) fibroblast-myofibroblast differentiation, regulation of 
fibroblast proliferation and control of fibroblast apoptosis. 
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2.6 The SMA positive myofibroblast 
 
The myofibroblast is a fibroblast which has acquired contractile stress fibers composed of 
cytoplasmic actins. These stress fibers allow for cell migration and increased 
contractility. Persistent activation leads to the development of a specific actin isoform, α-
SMA, which allows for more effective contractility (Hinz, 2007; Hinz et al., 2007). SMA 
positivity is the main immunohistochemical method of identifying myofibroblasts. As 
myofibroblasts are typically absent in non-fibrotic tissue, the origin of myofibroblasts has 
been a topic of considerable interest. Like with other dermal fibroblasts, local 
transformation of quiescent resident fibroblasts, trans-differentiation of epithelial or 
endothelial cells and a circulating fibrocyte precursor represent the main theories of 
myofibroblast origin (Hinz et al., 2007). More recent work has suggested pericyte, 
macrophage or adipocyte origins for fibrosis associated myofibroblasts (Humphreys et 
al., 2010; Martins et al., 2015; Meng et al., 2016). While all are interesting hypotheses, 
for the purpose of this study, only the first will be reviewed in detail. 
 
Myofibroblastic differentiation of quiescent fibroblasts is thought to require a 
combination of increased mechanical stress within the ECM, cytokine stimulation and 
interaction with specific ECM proteins (Hinz, 2010; Hinz et al., 2007). After wounding, 
various cytokines and growth factors activate fibroblasts (Figure 1) which begin 
production of ECM components leading to a disruption of its pre-injury cross-linked 
structure, and an increase in ECM stiffness (Wipff & Hinz, 2009). The resultant 
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mechanical challenge induces the formation of cytoplasmic actin stress fibers as 
discussed above. In conjunction with this mechanoinduction differentiation pathway, 
TGF-β secreted from macrophages, keratinocytes and resident fibroblasts themselves, 
acts a potent cytokine inducer of a myofibroblastic phenotype (Gabbiani, 2003). It is 
interesting that the previously detailed study and others suggests that CD90 expression 
may be a prerequisite for optimal TGF-β secretion, acting as an upstream inducer of 
myofibroblast differentiation. This upstream role is supported by evidence suggesting 
CD90 expression occurs prior to SMA
+
 myofibroblast differentiation (Koumas, Smith, 
Feldon, Blumberg, & Phipps, 2003; Schmidt et al., 2015; Yuasa et al., 2013). Finally, the 
interaction of fibroblasts with TGF-β dependent ECM protein ED-A splice variant of 
fibronectin (ED-A FN) seems to precede and be necessary for induction of a 
myofibroblastic phenotype. Again, the upstream role of CD90 in expression of ED-A FN 
has been described, intimately linking this protein to the major fibroblast → 
myofibroblast differentiation pathways. After ECM stability and re-epithelialization has 
been achieved, myofibroblasts  disappear from the wound bed traditionally explained by 
massive fibroblast apoptosis (also linked to CD90 expression) (Gabbiani, 2003). Previous 
research indicates that myofibroblasts appear by day 6 and are completely absent after 
day 30, coinciding with the presence of increased apoptotic figures (Darby, Skalli, & 
Gabbiani, 1990).  
 
It should be mentioned that pathologic fibrosis has, in many conditions (including scars), 
been attributed primarily to the abnormal persistence of the myofibroblast (Badid, 
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Mounier, Costa, & Desmoulière, 2000; Darby & Hewitson, 2007; Kis, Liu, & Hagood, 
2011; Santucci, Borgognoni, Reali, & Gabbiani, 2001; Sarrazy, Billet, Micallef, 
Coulomb, & Desmoulière, 2011; Tomasek, Gabbiani, Hinz, Chaponnier, & Brown, 2002; 
Wynn, 2008). While their presence and remodeling/contractile role in these conditions 
are widely accepted, the evidence supporting their role as the main contributors to 
production of the ECM and scar collagenization characteristic of all fibrotic pathology is 
less clear. 
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CHAPTER THREE: AIMS AND HYPOTHESES  
 
3.1 Study Aims 
 
The basic aims of this study are to define scar fibroblast phenotypes in cutaneous scars, 
and to determine similarities or differences between these protein expression patterns in 
reparative, hypertrophic and keloidal scars. In specific, it examines for the expression 
patterns of CD90 (Thy-1), CD34 and SMA within these scar groups, and attempts to 
delineate the spatial relationships between these various fibroblast populations and the 
comparative contributions of each fibroblast-type to scar mass.  This study also examines 
for evidence of fibroblast transitioning from the background CD34
+
 stromal cell network, 
using the presence/absence of fibroblasts exhibiting double positivity for the various 
protein markers. Evaluation will be performed with double-stained 
immunohistochemistry and immunofluorescence studies. Additionally, this work aims to 
delineate a timeline for the loss/neo-expression of the various markers after wounding 
and explores for evidence of reversion to the quiescent pre-wounding state or persistence 
of an activated scar fibroblast phenotype. Finally, contribution to ECM production by the 
various fibroblast-types, as it relates to scar collagenization, will be evaluated for via 
expression of procollagen-1.  Based on the literature reviewed in the previous chapter and 
investigator driven postulation, a hypothetical model of scarring was developed and is 
represented in Figure 4. 
 
  
23 
3.2 Proposed hypothetical model of fibroblast transitions in cutaneous scarring 
 
 
Figure 4. Hypothetical model of fibroblast transitions in simple reparative scars 
[1] After injury, quiescent background CD34
+
 fibroblastic stromal cells undergo a change 
in protein expression profile and begin to express CD90. [2] CD90
+
/CD34
- 
fibroblasts lay 
down collagen and increase TFG-β and EDA-FN leading to development of the well-
established scar. Resultant cytokine stimulation and changes to ECM mechanics induces 
partial myofibroblastic transition. [3] CD90 expression regulates fibroblast 
apoptosis/proliferation leading to a low-cellularity scar. When ECM homeostasis is 
achieved, re-transition to CD34
+
/CD90
-
 fibroblastic stromal cell network begins with 
complete reversion in the mature scar  
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CHAPTER 4: MATERIALS AND METHODOLOGY 
 
 
4.1 Specimen selection, scar classification and scar aging 
 
Boston Medical Center’s institutional review board approved all procedures and data 
analysis. Specimens diagnostically coded as “scar”, “hypertrophic scar” or “keloid” were 
identified and then retrieved via the database of Skin Pathology Laboratory at Boston 
University School of Medicine. Standard hematoxylin and eosin (H&E) sections were 
reviewed for histologic inclusion criteria (see below) and specimens were classified as 
simple reparative scars (n=47), hypertrophic scars (n=40) or keloidal scars (=30). 
Additionally, specimens exhibiting normal skin from uninvolved adjacent tissue sections 
in excision specimens containing simple reparative scars were identified for control 
purposes (n=10). 
 
As all simple reparative scars selected were from excision specimens of previously 
biopsied lesions, an accurate scar age could be calculated for these specimens by 
subtracting the date of initial biopsy performed from the date of the excision. Where the 
information was available, exact scar age was also calculated for hypertrophic scars 
(n=23) and keloids (n=13), though in many instances no clinical data was provided to 
assist with aging the scars. Where clinical data regarding the age of the scar was available 
but not explicit, the minimum age was recorded. As such, a hypertrophic scar/keloid 
recorded as “present for many years” or “present for greater than six months” was 
  
25 
recorded at its minimum age of 365 days or 180 days respectively. Scar age was recorded 
in days, and subsequently categorized as <30 days (<1 month), 30–89 days (1–3 months), 
90–179 days (3–6 months) and >180 days (> 6 months).  
 
4.2 Histologic criteria for scar classification 
 
Simple reparative scars (n=47) 
Classification as a simple reparative (Figure 5) scar relied on fulfillment of the following 
criteria:  
i. Excision specimens/recurrence biopsy specimens  
ii. Increased fibroblast proliferation and collagen production (early/proliferating 
scars) 
OR 
Parallel dermal fibrosis and low cellularity with vertically oriented blood vessels 
(“aged” histologic appearance) 
iii. No large nodular or broad fascicular component 
iv. No keloidal collagen formation 
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Figure 5. Histologic appearance of simple reparative scars Early cellular scars (A–B) 
demonstrate increased numbers of plump fibroblasts in addition to parallelly arranged 
collagen bundles and vertically oriented blood vessels. Note similar architectural 
abnormalities but low-cellularity in histologically “aged” scars (C–D). Original 
magnification: A, C  X20; B, D  X100 
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Hypertrophic scars (n=40) 
 
Classification as a hypertrophic scar (Figure 6) relied on fulfillment of the following 
criteria: 
i. Large well defined fibroblast rich nodules or large fascicles with fibrillar collagen 
(active/cellular histologic appearance) 
OR 
Well defined nodular/fascicular arrangement of fibrotic collagen and scar-type 
vasculature (aged histologic appearance) 
ii. Absent keloidal collagen 
OR 
 If keloidal collagen present, should represent a minor component of the total scar 
(<10%) and be limited to center of the scar nodule/fascicle 
 
Note: While classically hypertrophic scars are taught to be completely devoid of keloidal 
collagen, in daily practice, focal keloidal collagen is frequently noted in otherwise typical 
hypertrophic scars. Because of this, lesions with an extremely well defined 
nodular/fascicular architecture characteristic of a hypertrophic scars but with a small 
amount of keloidal collagen were classified in this study as the former, though note was 
made of the presence/absence of focal keloidal collagen 
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Figure 6. Histologic features of hypertrophic scars A well-defined fibroblastic nodule 
in the deep dermis characteristic of a hypertrophic scar (A–C). Note focal keloidal 
collagen in an otherwise typical hypertrophic scar nodule (C). Original magnification: A 
x20; B X100; C X40 
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Keloidal scars (n=30) 
 
Classification as a keloid (Figure 7) relied on fulfillment of the following criteria: 
 
i. Expansive nodule with >10% composed of typical keloidal collagen 
ii. Poorly defined borders with proliferative “tongues” at the specimen 
margins 
OR  
Extensive keloidal collagen but with a somewhat well-defined 
nodular/fascicular architecture reminiscent of hypertrophic scar-like 
architecture  
 
Note: Similar to the above caveat for hypertrophic scars, occasional keloids were 
encountered with an architecture more reminiscent of a hypertrophic scar but with such 
extensive keloidal collagen, that histopathologic designation of hypertrophic scar would 
be difficult based on current diagnostic convention. As such these lesions were classified 
as keloids but the presence of typical versus hypertrophic scar-like architecture was 
recorded as a sub-categorization.    
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Figure 7. Histologic appearance of keloidal scars Note the expansile nature of a keloid 
with typical architecture (A–B), with a characteristic elevated appearance compared with 
surrounding normal skin and an infiltrating base (A). Large amounts of disorganized, 
eosinophilic collagen (keloidal collagen) are present (B) along with scattered large 
fibroblasts (B). Occasional extensively collagenized keloids do not elevate the skin and 
have a relatively circumscribed architecture somewhat reminiscent of a hypertrophic scar 
(C–D). Note the keloidal collagen and a rim of normal dermis subjacent to the scar, 
highlighting its relative circumscription (D). Original magnification: A, C X20; BX200; 
C X40 
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4.3 Immunohistochemistry and immunofluorescence protocols 
 
All immunohistochemistry/immunofluorescence (IHC/IF) was performed on formalin 
fixed paraffin embedded tissue. Double and single staining protocols (modified from 
those described by Nazari et al., 2016) were applied to all specimens. After 
deparaffinization, hear antigen retrieval was performed with Tris-
Ethylenediaminetetraacetic acid (EDTA) at pH 9.0. Subsequent protein blocking was 
performed with 3% H2O2 followed by endogenous peroxidase and alkaline phosphatase 
blockade with either BloxAll (Vector Labs®, Burlingame, CA) or dual endogenous 
enzyme block (Dako Inc.® Denmark). Further blocking with 2.5% normal horse serum 
was performed prior to primary antibody incubation. Primary antibodies utilized in this 
study (see Table 2 for dilutions) included monoclonal rabbit anti-human CD90 (clone: 
EPR3132, Abcam®), monoclonal mouse anti-human CD34 (clone: QBEnd 10, Dako®), 
monoclonal mouse anti-human SMA (clone: 1A4, Dako®) and monoclonal rat anti-
human procollagen type 1, N-terminal (clone: M-58, Chemicon®). Horse anti-
rabbit/mouse/rat (mouse adsorbed as necessary) immunoglobulin (horseradish peroxidase 
[HRP]/alkaline phosphatase) polymer detection kits were appropriately utilized 
(ImmPress™, Vector Labs® Burlingame, CA) and chromogen development was 
performed with either AMEC red (HRP, ImmPact Vector labs®, Burlingame, CA) or 
HighDef™ blue (alkaline phosphatase Enzo Life Sciences Inc. ®). In the case of the 
double-staining protocol, quenching with H2O2 was performed after chromogen 
development of the first primary antibody and prior to incubation with the second. Dual 
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CD90/CD34 staining was performed on all specimens to assess for single cell dual 
positivity as evidence of mesenchymal transition. Additionally, all samples were 
evaluated for SMA expression. SMA positivity was primarily assessed via a single stain 
protocol but a subset of specimens was double-stained with CD90/SMA (n=26) to 
examine for single cell dual positivity and more accurately appraise the spatial 
relationship between fibroblasts expressing these two proteins. Similarly, a subset of 
specimens was double stained with procollagen-1 (PC-1)/CD90 (n=18) or PC-1/SMA 
(n=8) in order to demonstrate the presence of collagen synthesis and to determine the 
relative contribution of the various fibroblast phenotypes to ECM production. 
 
Double-stained IF with CD90/CD34 was performed on 3 reparative scars and a similar 
protocol was adhered to with the exception of polymer detection which was performed 
with Alexa Fluor 488 and Alexa Fluor 594 tyramide reagents (Thermo Fisher 
Scientific®, Waltham, MA). IF imaging was executed using confocal laser microscopy 
(FlouView FV10i, Olympus® Waltham, MA). 
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Antibody Dilution Incubation 
CD90 (Thy-1) 
[EPR3132, Abcam®] 
1:1200 (IHC*) 
1:3000 (IF*) 
Overnight (12 hours) 
Overnight (12 hours) 
CD34 
[QBEnd 10, Dako®] 
1:400 (IHC) 
1:2500 (IF) 
60 minutes 
90 minutes  
SMA  
1A4, Dako® 
1:500 (IHC) 60 minutes 
Procollagen type 1 
M-58, Chemicon® 
1:300 (IHC) 30 minutes 
 
Table 2  Dilutions and incubation times for primary antibodies 
* IHC, immunohistochemistry; IF immunofluorescence 
 
4.4 Histologic grading of protein expression 
 
In addition to recording dichotomous positive or negative expression of a given marker, 
for a more complete analysis, protein expression was also graded using the following 
system: 
i. Diffuse expression: >50% of fibroblasts within main body of the scar express 
protein 
ii. Focal expression: <50% of fibroblasts within main body of the scar express 
protein but more than rare single cell positivity 
iii. Rare expression:  scattered single cell positivity within the main body of the scar 
iv. Negative: No positivity within main body of the scar 
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With regards to fibroblast dual marker expression (CD90/CD34, CD90/SMA, CD90/PC-1 
and SMA/PC-1), positivity was recorded only when clear double-positivity within a single 
cell was observed. For ease of statistical analysis, the presence/absence of a specific 
marker, the presence/absence of dual positive cells and categories of expression were 
assigned a numerical value ranging such that dichotomous ‘present/absent’   expression 
was recorded as ‘0’ or ‘1’ respectively and expression patterns were graded as 0–3 
(negative → diffuse expression). It should be specifically mentioned that with regards to 
dual CD34/CD90 expression, double positive cells identified only at the periphery of scars 
(but not within the main scar) were interpreted as cells in-transition and would be recorded 
as present dual positivity but in the absence of expression in the main body of fibrosis, 
general scar expression of CD34 would be recorded as negative. 
 
4.5 Statistical Analysis 
 
 Statistical analysis was performed using the Statistical Package for the Social Sciences 
(SPSS version 23). As described above categorical/dichotomous variables were generated 
based on scar type (reparative/hypertrophic/keloidal scar) the presence or absence of a 
particular IHC marker (CD90/CD34/SMA/PC-1), the expression pattern of that marker, 
presence or absence of dual positive CD90/CD34 fibroblasts. Additional variables were 
created for the subset of specimens on which additional double-staining for CD90/SMA, 
CD90/PC-1 and SMA/PC-1 was performed, including variables designed to reflect 
spatial relationships and the relative contribution of each fibroblast type within a given 
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scar (e.g. CD90+ fibroblasts greater than/less than/equal to SMA+ fibroblasts, PC-1 
expression limited to/extending beyond SMA rich areas etc.). Categorical variables were 
also constructed for combination of expression patterns (e.g. CD90 
diffuse
/CD34 
focal/rare/absent
, CD34
diffuse
/CD90
focal/rare/absent
 etc.). Where scar age was available, 
specimens were categorized as described above (see Section 4.1). Specimens with 
missing data (limited to ages of hypertrophic scars and keloids) were not included in the 
relevant analyses.  
 
For scars categorized as hypertrophic or keloidal, additional dichotomous variables were 
created reflecting the presence or absence of keloidal collagen and the architectural 
pattern (typical-keloid vs. hypertrophic scar-like) respectively (see Section 4.2). 
 Descriptive statistics were generated for all variables and displayed in tabular or 
graphical form. All variables in this study were assigned numerical values and analyzed 
as categorical data. Association between variables was evaluated for using Chi-squared 
test of independence and where appropriate Fisher’s exact test. Results were considered 
significant at p≤0.05.   
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CHAPTER 5 RESULTS 
 
 
Overall, 117 specimens met the criteria for inclusion in this study, with 47 being 
classified as simple reparative scars, 40 as hypertrophic scars and 30 as keloidal scars. 
The results of the tested hypotheses are detailed below (Table 3).  
 
5.1 In normal skin, the reticular dermal stroma exhibits a CD34
diffuse
CD90
negative 
phenotype with CD90
+
 cells localized to the perivascular and periadnexal adventitial 
compartments 
 
When normal appearing skin was evaluated for a population of CD34
+
 or CD90
+
 
fibroblasts (n=10), the reticular dermal stromal compartment uniformly exhibited a 
CD34
diffuse
/CD90
negative
 phenotype (Figure 8). The CD34
+
 cells formed a dense and 
intricate network of interconnecting dendritic processes, consistent with the previously 
described CD34
+
 fibroblastic stromal cell network with its numerous long telopodes and 
multifocal cell-cell connections.(Manole & Simionescu, 2016) While these fibroblastic 
cells were ubiquitous, they lacked the distinct parallel architectural arrangement 
characteristic of scar fibroblasts, in keeping with their quiescent state. In the perivascular, 
perifollicular and peri-eccrine adventitia, an admixture of CD34
+ 
and CD90
+ 
fibroblasts 
(sharply delimited to these compartments) was observed. In the perivascular and 
perifollicular locations, occasional double-positive CD34/CD90 fibroblasts were noted. 
  
37 
These findings are consistent with those previously reported for expression patterns of 
CD90 and CD34 in the skin.(Nazari et al., 2016) 
 
 
 
Figure 8. Regional expression of CD34 and CD90 in normal human skin The normal 
dermis is characterized by diffuse CD34 positivity corresponding to the resident stromal 
fibroblastic cell network. These quiescent fibroblasts form an intricate interstitial 
network, with increased concentration around adnexae (A). CD90 expressing fibroblasts 
are absent in the unperturbed interstitial reticular dermis but positive cells are noted 
within the periadnexal (B) and perivascular (C) adventia. Note dual CD90/CD34 
expressing fibroblasts in a perifollicular and perivascular location (B, C). Original 
magnification A X20; B X200; C X100 
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5.2 Simple reparative scars, hypertrophic scars and keloids are most commonly 
characterized by a CD90
diffuse
/CD34
negative/minority
 fibroblast phenotype 
 
When scar specimens (n=117) were evaluated for the presence of CD90 expressing 
fibroblasts within the main body of the scar, such a population was identified in 96.6% 
(n=113) of all scars examined. When individual scar types (reparative, hypertrophic and 
keloidal) were examined for fibroblast CD90 expression, reparative, hypertrophic and 
keloidal scars exhibited a population of CD90
+
 fibroblasts within the scar in 93.6% 
(n=44), 97.5% (n=39) and 100% (n=30) of specimens respectively (Table 3). There was 
no significant association between presence of a CD90
+
 fibroblast population and scar 
type (p=0.3). When CD90 expression pattern (diffuse/focal/rare/negative) was evaluated, 
a CD90
diffuse
 pattern was observed in 88.9% (n=104) of all scars examined. Scar-type 
group analysis revealed 80.9% (n=38) of reparative scars, 90% (n=36) of hypertrophic 
scars and 100% (n=30) of keloids demonstrated a CD90
diffuse
 expression pattern (Figure 
9). In scars with a CD90
diffuse
 expression pattern, the histologic outline of the fibrosis was 
clearly delineated by the interface of scar CD90
+
 fibroblasts and the junction of the 
background CD34
+ 
fibroblastic stromal cell network, imparting an inverse imprint 
appearance (Figure 10). While there was no statistically significant association between 
CD90 expression pattern and scar type (p=0.14), it was interesting to note that keloids 
never demonstrated a CD90
negative/minority
 phenotype [a “minority” phenotype refers to 
scars where true positivity is noted, but only in a minority of fibroblasts. It is a composite 
designation representing a combination of specimens exhibiting a rare/focal expression 
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pattern]. This pattern was however observed in both reparative and hypertrophic scars, 
though it was more common in reparative scars (19.1%, n=9) than in hypertrophic scars 
(10%, n=4) (Figure 9). Based on the proposed model of fibroblast transitions in scarring 
(see Section 3.2, Figure 4), the presence of a CD90
negative/minority
 population in reparative 
scars is consistent with the concept that as fibroblasts become inactive (trending towards 
the pre-wound state) they are characterized by a loss of CD90. The observation that a 
subset of hypertrophic scars also exhibit such a population, correlates with the known 
natural history of spontaneous (albeit delayed) involution witnessed in occasional scars of 
this subtype. The lack of a CD90
negative/minority
 in keloids is also congruent with their 
clinical course, typified by a tendency to indefinite growth.  
 
When the presence of CD34
+
 fibroblasts within the main scar body (defined 
bands/nodules/fascicles of fibrosis) was examined for, overall 83.8% (n=97) of all scars 
had a negative or only focally/rarely identified (minority phenotype) CD34 population. 
When CD34 expression patterns were examined among individual histologic scar type 
groups, a negative/minority CD34 expression pattern was also the most commonly 
observed pattern, accounting for 82.9% of all scars (n=97), 80.9% (n=38) of simple 
reparative scars, 72.5% (n=29) of hypertrophic scars and 100% (n=30) of keloids (Figure 
11). Taken together, among all scars and within each histologic scar group, a 
CD90
diffuse
/CD34
negative/minority 
expression pattern is the most commonly observed scar 
fibroblast phenotype. 
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 Reparative 
Scars n=47 
 (%) 
Hypertrophic 
Scars n=40 
(%) 
Keloidal 
Scars n=30  
(%) 
Total 
n=117 
(%) 
CD90 + fibroblasts within scar 
body (any positivity) 
93.6 (n=44) 97.5 (n=39) 100 (n=30) 96.6 (n=113) 
CD34+ fibroblasts within scar 
body (any positivity) 
25.5 (n=12) 60.0 (n=24) 53.3 (n=16) 44.4 (n=52) 
SMA+ myofibroblasts within scar 
body (any positivity) 
66.0 (n=31) 75.0 (n=30) 90.0 (n=27) 75.2 (n=88) 
C90 Expression pattern 
o CD90 Diffuse 
 
o CD90 Negative/minority 
 
– CD90 Negative  
 
– CD90 Rare  
 
– CD90 Focal  
 
80.9 (n=38)  
 
19.1 (n=9) 
 
6.4 (n=3) 
 
10.6 (n=5) 
 
2.1 (n=1)  
  
90.0 (n=36) 
 
10.0 (n=4) 
 
2.5 (n=1) 
 
2.5 (n=1) 
 
5.0 (n=2) 
 
100.0 (n=30) 
 
0 
 
0 
 
0 
 
0 
 
88.9 (n=104) 
 
11.1 (n=13) 
 
3.4 (n=4) 
 
5.1 (n=6) 
 
2.6 (n=3) 
CD34 Expression pattern 
o CD34 Diffuse 
 
o CD34 Negative/minority 
 
– CD34 Negative  
 
– CD34 Rare 
  
 
– CD34 Focal  
 
17 (n=8) 
 
83.0 (n=39) 
 
76.6 (n=36) 
 
0 
 
6.4 (n=3) 
 
27.5 (n=11) 
 
72.5 (n=29) 
 
40.0 (n=16) 
 
2.5 (n=1) 
 
30.0 (n=12) 
 
0 
 
100.0 (n=30) 
 
46.7 (n=14) 
 
16.7 (n=5) 
 
36.7 (n=11) 
 
16.2 (n=19) 
 
83.8 (n=98) 
 
56.4 (n=66) 
 
5.1 (n=6) 
 
22.2 (n=26) 
SMA Expression pattern 
o SMA Diffuse 
 
o SMA Negative/minority 
 
– SMA Negative  
 
– SMA Rare 
 
– SMA Focal  
 
36.2 (n=17) 
 
63.8 (n=30) 
 
34.0 (n=16) 
 
12.8 (n=6) 
 
17.0 (n=8) 
 
52.5 (n=21) 
 
47.5 (n=19) 
 
25.0 (n=10) 
 
5.0 (n=2) 
 
17.5 (n=7) 
 
40.0 (n=12) 
 
60.0 (n=18) 
 
10.0 (n=3) 
 
13.3 (n=4) 
 
36.7 (n=11) 
 
42.7 (n=50) 
 
57.3 (n=67) 
 
24.8 (n=29) 
 
10.3 (n=12) 
 
22.2 (n=26) 
Dual CD90+/CD34+ fibroblasts  85.1 (n=40) 92.5 (n=37) 96.7 (n=29) 90.6 (n=106) 
Keloidal collagen present N/A 35.0 (n=14) 100.0 (n=30) N/A 
Hypertrophic Scar-like 
architecture 
N/A N/A 36.7 (n=11) N/A 
 
Table 3. Summarized descriptive statistics of reparative, hypertrophic and keloidal 
scars 
 A “minority” phenotype includes a combination of rare/focal expression patterns 
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Figure 9. CD90 expression 
patterns based on scar type  
While diffuse CD90 
expression was the most 
pattern in all scar groups, a 
CD90
negative/minority
  pattern 
(boxed) was never observed in 
keloids and more likely in 
reparative scars (19.1%, n=9) 
than hypertrophic scars (10%, 
n=4). There was no 
statistically significant 
association between CD90 
expression pattern and scar 
type (p=0.14)  
(

 Minority phenotype defined 
as any scar with a rare/focal 
expression pattern) 
            
           
           
            
 
 
 
I 
Negative/minority 
expression pattern 
CD90 negative/minority phenotype 
Diffuse expression 
Focal expression 
Rare expression 
No expression 
0 
CD90 negative/minority phenotype 
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Figure 10.  A CD90
diffuse
/CD34
-/minority
 phenotype in cutaneous scars This was the 
most commonly observed pattern in reparative scars (A), hypertrophic scars (B) and 
keloids (C). Note frequently identified “inverse imprint” relationship, between CD90 and 
CD34 clearly highlighting the main scar body (A, B). Original magnification  A–C  X20  
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Figure 11. CD34 expression 
patterns based on scar type  
Among all scar groups, a 
CD34
negative/minority
 (boxed) 
was the most common 
expression pattern (83.8%, 
n=98), although diffuse 
CD34 expression (a CD34 
revertant state) was observed 
in a subset of simple 
reparative (17%, n=8) and 
hypertrophic scars (27.5%, 
n=11), but never in keloids. 
There was a statistically 
significant association 
between CD34 expression 
pattern and scar type 
(p<0.0001). Absent 
expression pattern categories 
in the adjacent graphs 
indicate that no scar in that 
group expressed the missing 
pattern (n=0) 
(

 Minority phenotype is 
defined as any scar with a 
rare/focal expression pattern) 
 
                  
 
 
 
CD34 negative/minority phenotype 
Diffuse expression 
Focal expression 
Rare expression 
No expression 
CD34 negative/minority phenotype 
CD34 negative/minority phenotype 
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5.2 All scar types demonstrate CD90/CD34 dual positive fibroblasts suggestive of 
local transition from the background CD34+ fibroblastic stromal cell network 
 
As previously detailed, this study hypothesizes that the background CD34
+
 fibroblastic 
stromal cell network serves as a mesenchymal progenitor pool which after injury loses its 
CD34 expression in exchange for CD90 expression. One method of evaluating for this 
transition would be to assess for the presence of fibroblasts expressing both proteins 
within a single cell via immunohistochemistry (IHC) and/or immunofluorescence (IF).  
 
With IHC, dual CD90/CD34 positive fibroblasts were identified in 90.6% (n=106) of all 
scars examined and were found in 85.1% (n=40) of reparative scars, 92.5% (n=37) of 
hypertrophic scars and 96.7% (n=29) of keloids (Figures 12, 13). In the majority of 
specimens, CD34 expression was identified at the scar periphery corresponding to the 
interface between the unaffected background CD34
+ 
fibroblastic cell network and scar 
fibrosis, congruent with the notion that CD90
+
 fibroblasts are derived from the 
surrounding quiescent network. These double positive fibroblasts were easily identified 
in the vast majority of cases. When double color immunofluorescence was performed on 
three reparative scars to assess for dual positive fibroblasts, numerous cells clearly 
displaying both proteins within a single cellular process were frequently observed 
(Figure 14). The morphology of these cells was consistent with either fully mature scar 
fibroblasts or exhibited delicate dendritic processes characteristic of stromal fibroblastic 
cell telopodes. Like with IHC evaluation, dual-positive cells were predominantly 
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identified at the boundary of the main scar (CD90
diffuse
 with no CD34 co-expression) and 
the uninvolved dermal stromal network (CD34
diffuse
 with CD90 co-expression). While 
vascular endothelium expresses CD34 and the surrounding perivascular adventitia and 
pericytes may express CD90, misinterpretation of vessels as fibroblasts is improbable as 
vessel morphology and distribution are clearly unalike that of a fibroblast, an easily 
appreciable distinction. Overall these findings are interpreted as evidence supporting the 
proposed CD34→CD90 transition hypothesis.  
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Figure 12. Examples of dual expressing CD90
+
/CD34
+
 fibroblasts in cutaneous scars 
Fibroblasts expressing both CD90 and CD34 within a single cell (arrows). Dual 
expressing cells were most commonly seen at the interface between the main scar body 
(SB) and the background CD34+ stromal cell network (BG). These co-expressing cells 
were present in reparative (A), hypertrophic (B) and keloidal scars (C). Original 
magnification A, B X40 (L), X200 (R); C X100 (L), X200 (R) 
  
SB 
BG 
SB 
SB 
BG 
BG 
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  Figure 13. High 
magnification examples 
of dual expressing 
CD90
+
/CD34
+
 fibroblasts 
Note high power examples 
of fibroblasts expressing 
both CD90 and CD34 
within a single cell 
(arrows) in a reparative 
scar (A), a hypertrophic 
scar (B) and a keloid (C).  
Original magnification A-
C x400 
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Figure 14. Dual expressing CD90
+
/CD34
+
 fibroblasts in cutaneous scars confirmed 
with double color immunofluorescence 
An example of the CD90
diffuse
/CD34
negative 
phenotype observed in the main scar body (A). 
Note dual expressing CD90
+
/CD34
+
 fibroblasts at the scar-background interface (B–C) 
with some examples demonstrating extensive dual expression (C, D). Original 
magnification A–D X600 
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5.3 In simple reparative scarring, a CD90
diffuse
/CD34
negative/minority 
phenotype is a 
time-limited and reversible phenomenon eventuating in return of the homoeostatic 
CD34
diffuse
/CD90
negative
 state:  a “CD34 revertant phenotype” 
 
The goal of cutaneous repair is achievement of as close an approximation of the pre-
wounded tissue state as possible. This study hypothesizes that in physiologic scarring, 
when maximal repair has occurred, the scar fibroblast protein expression returns to the 
pre-injury phenotype. We also propose that in the non-pathologic state, scar reversion 
would follow a general and reproducible time-line. In order to test this hypothesis, 
reparative scars were dated according to their age in days and further grouped into age 
categories as follows: <30 days (< 1 month), 30–89 days (1–3 months), 90–179 days (3–6 
months) and > 180 days (>6 months) (see Section 4.1). When CD90 expression was 
assessed for based on scar age (Figure 15), all scars younger than 89 days (~ 3 months) 
were characterized by a CD90
diffuse
 expression pattern. Scars ranging between 90–179 
days (3–6 months) could still express CD90 diffusely, but 2 scars in this category 
demonstrated a negative/minority profile. At greater than 160 days, no scar had a 
CD90
diffuse
 pattern with all exhibiting a CD90
negative/minority
 phenotype (only negative 
staining or rare single cell positivity was seen in these cases, Figure 16). Interestingly, 
when a 2-day old wound was examined for CD90 expression, diffuse transition to CD90 
had already occurred. Fascinatingly, widespread dermal CD90 expression was noted far 
beyond the lateral and deep margins of the visible wound, extending deeply into the 
septae and lobules of the underlying subcutis and even involving the adjacent tissue 
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section with an intact epidermis and no evidence of dermal injury (Figure 17). A similar 
diffuse pattern was also noted in scars aged 8, 14 and up to ~30 days. This pattern 
contrasts sharply with the inverse area imprint appearance seen in well-developed scars 
(Figure 10) and raises the possibility that early transition is less discriminatory, affecting 
the large regions of involved and clinicopathologically uninvolved skin and subjacent 
adipose tissue. Together, these data suggest that CD90 expression in fibroblasts appears 
rapidly after wounding (as early as 48 hours) in a diffuse, non-scar-outlined pattern which 
may persist up until 1 month, followed by diffuse CD90 expression within a well-
outlined scar (inverse imprint pattern) up until ~3+ months of age. Between 3–6 months 
of age, some scars begin to lose their CD90 expression with subsequent significant loss 
of CD90 expression occurring in scars >160–180 days of age. 
 
When CD34 expression was examined for based on scar age, the inverse expression 
pattern (as anticipated) was observed. All scars younger than 90 days had a 
CD34
negative/minority
 pattern, 2 scars between 90–179 days displayed a revertant CD34diffuse 
pattern, the youngest of which was 98 days. All 7 scars older than 160 days (6 scars > 
180 days) demonstrated a CD34
diffuse
. In keeping the reciprocal staining pattern of CD34 
and CD90 and the age-dependent pattern of expression observed for CD90, scars lose 
CD34 rapidly after wounding and continue to express a CD34
negative/minority
 phenotype 
until between 90–180 days when there seems to be the beginning of the return of the pre-
wound CD34
diffuse
 state. Complete return of a CD34
diffuse
 appears to occur after 160–180 
days in reparative scars. Furthermore, the disappearance CD34 mirrors the initial 
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appearance of CD90 and likewise the reappearance of CD34 corresponds to the 
disappearance of CD90, providing further evidence of the reciprocal nature of these 
proteins (Figure 21). In simple reparative scars, CD90 expression pattern was 
significantly associated with CD34 expression pattern (p<0.0001). This reappearance of 
CD34, felt to represent the maximal return to pre-injury status, is hereafter termed a 
“CD34 revertant state”. The histologic appearance of the revertant state is one of a low-
cellularity scar with retention of its cicatrized collagen architecture (Figure 16- C). As 
expected, in simple reparative scars there exists a statistically significant association 
between both CD90 and CD34 expression patterns and scar age (p<0.0001). 
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Figure 15. Age based 
expression of CD90 
and CD34 in 
reparative scars   
All scars younger than 
90 days exhibited a 
CD90
diffuse
CD34
-/minority
 
phenotype. Loss of a 
diffuse CD90 pattern is 
accompanied by a return 
of diffuse CD34 
positivity (a CD34 
revertant state), and was 
observed in all scars> 
160 days (time point not 
indicated). Scar age was 
significantly associated 
with expression patterns 
of both CD90 and CD34 
(p<0.0001) 
(Minority phenotype is 
defined as any scar with 
a rare/focal expression 
pattern) 
 
 
 
 
                  
 
 
Diffuse 
 
Negative/
minority 
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Figure 16. Stages of scar fibroblast activation and reversion As early as 48 hours after 
wounding there is loss of CD34 and extensive expression of CD90 (A, see Figure 17). 
This phase may last until approximately 30 days and is followed by diffuse CD90 
expression delimited to a well-defined scar, lasting until 160 days (B). Loss of CD90 
positivity and diffuse re-expression of CD34 occurs as early 98 days and in all scars 
between 160–180 days (C). Original magnification A, B X20; C x40   
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Figure 17. Loss of CD34 and extensive indiscriminate expression of CD90 48 hours 
after injury Note pan-dermal loss of CD34 and concurrent expression of CD90 in 
injured skin (D–F) compared with normal skin (A–C) with transition extending far 
beyond the visible wound (E, F) and even involving the fat septae (F). Fascinatingly, 
adjacent tissue sections (~ 3mm away) with undamaged intact epidermis (G) also 
exhibited a loss of CD34 and neo-expression of CD90 (H, I) extending into the subcutis 
(I). Original magnification A, B, D, E, G, H X20; C, F, I X40 
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5.4 A CD34 revertant (CD34
diffuse
) phenotype is observed in reparative scars and 
hypertrophic scars, but not in keloids  
 
A revertant phenotype was examined for in pathologic scars. Interestingly, a revertant 
phenotype was also observed in 27.5% (n=11) of hypertrophic scars and this finding is 
consistent with the clinical resolution reported to occur in a subset of hypertrophic scars 
(Figure 18). A revertant phenotype was not observed in any keloid. As expected based 
on these observations and those detailed above, there was a statistically significant 
association (p=<0.0001) between CD34 expression pattern and histologic scar type and 
specifically, between histologic scar type and a revertant phenotype (CD34
diffuse
 pattern) 
(p=0.014). These data support the suggestion of CD34 reversion as a biologic 
phenomenon occurring in reparative scars and a subset of histologically aged 
hypertrophic scars. The finding that a revertant state was not observed in keloids is also 
compatible with their known natural history of persistence. Additionally, when CD90 
expression pattern was evaluated in scars which exhibited a CD34 revertant phenotype, a 
peculiar difference in the CD90 expression patterns was detected. 8 of 9 revertant 
reparative scars demonstrated a CD90
negative/minority 
/CD34
diffuse
 reversion pattern whereas 
7 of 11 revertant hypertrophic scars displayed the opposite CD90
diffuse
/CD34
diffuse
 pattern. 
These findings raise the possibility of a difference in reversion pathways between 
reparative and pathologic scars. 
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Figure 18. A revertant hypertrophic scar Note the low-cellularity nodules (A, circled) 
and fibrous fascicles (A, boxed) characteristic of aged hypertrophic scars. Higher 
magnification of a nodule reveals rare fibroblasts, some of which are CD90
+
 (B inset, red 
arrows) and many which are procollagen I (PC-1) 
+
 indicative of active collagen 
synthesis (B inset, blue arrows). There is however generalized return of CD34 positivity 
(CD34 revertance, C), though many of the CD34
+
 fibroblasts continue to express CD90 
(D). Original magnification A, C X40; B, D X200 
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5.5 Keloids and a subset of hypertrophic scars are characterized by a prolonged 
CD90
diffuse
 fibroblast phenotype 
 
As discussed above, in simple reparative scars complete reversion is associated with loss 
of CD90 and re-expression of CD34. While clinical data allowing for scar aging was 
lacking in a number of hypertrophic scars and keloids, we were able to date significant 
subset of these entities. In total 23 hypertrophic scars were dated, with ages ranging from 
32 days to 1098 days. Twelve hypertrophic scars aged 180–1098 days were identified, 
and of these, nine (75%) displayed a CD90
diffuse
 pattern. Thirteen keloids were dated and 
twelve were older had ages ranging between 300–3128 days. All keloids exhibited a 
CD90
diffuse
 pattern. These data suggest that a subset hypertrophic scars and keloids are 
characterized by a prolongation of their CD90
diffuse
 phenotype, potentially serving as 
further evidence that these entities may be diseases on a spectrum, but with keloids 
having more profound delay in losing their active fibroblast phenotype. 
 
5.6 Reparative and pathologic scars contain SMA+ myofibroblasts in varying 
proportions 
 
Next the presence of SMA expression in fibroblasts (classical myofibroblasts) and the 
associated expression patterns were examined for. Overall, among all scar groups, 75.2% 
(n=88) expressed SMA to some degree. In simple reparative scars, a near equal 
proportion of scars displayed a SMA
diffuse
 pattern (36.2%, n=17) or absent SMA 
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expression (34.78%, n=16). The remaining scars exhibited focal or rare SMA positivity 
therefore a SMA
 negative/minority
 phenotype was the most commonly observed pattern in 
simple reparative scars (63.8%). In hypertrophic scars 52.5% (n=21) exhibited a 
SMA
diffuse 
pattern with 17.5% (n=7) exhibiting focal positivity, 5.0% (n=2) demonstrating 
only rare single cells and 25% (n=10) were entirely negative for SMA. Among keloidal 
scars, 40% (n=12) diffusely expressed SMA, while 36.7% (n=11) exhibited focal SMA 
expression, 13.3% (n= 4) rare SMA expression and 10% (n=3) having no detectable 
SMA expression. A SMA
negative/minority
 phenotype (60%) was the most commonly 
observed pattern in keloids (Figure 19). Overall however, there was no significant 
association between scar type and SMA expression pattern (p=0.085) 
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 Figure 19. SMA expression 
patterns based on scar type  
All scar types were more 
likely than not to demonstrate 
SMA+ myofibroblasts to 
some degree. Unlike CD90 
however, diffuse fibroblastic 
expression of SMA was not 
observed in the 
overwhelming majority of 
cases. A SMA
-/minority positive 
phenotype was the most 
commonly observed pattern 
in simple reparative scars 
(63.8%, n=30) and keloids 
(60%, n=18). Hypertrophic 
scars displayed diffuse SMA 
positivity (52.5% n=21) in 
almost equal proportions to a 
negative/minority pattern. 
There was no significant 
association between SMA 
expression pattern and scar 
type (p=0.085) 
(

 Minority phenotype is 
defined as any scar with a 
rare/focal expression pattern) 
 
                  
 
 
 Diffuse expression 
Focal expression 
Rare expression 
No expression 
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5.7 In simple reparative scarring, the presence of SMA
+
 myofibroblasts is a time-
limited and reversible phenomenon  
Like CD90 expressing fibroblasts, in physiologic scarring, classical SMA
+ 
myofibroblasts 
also appear and disappear from scars in a time dependent manner. 87.1% (n=27) of scars 
between 0–89 days (0–3 months) had identifiable SMA+ myofibroblasts with 48.4% of 
scars expressing SMA diffusely (n=15). Interestingly, none of the scars between 90–180 
days expressed SMA diffusely with 71.43% (n=5) having no identifiable SMA
+
 
fibroblasts (Figure 20). No reparative scar older than 160 days exhibited SMA
+ 
myofibroblasts (n=7). The association between SMA expression pattern and scar age in 
reparative scars was statistically significant at p<0.0001. The pattern of SMA expression 
and loss thereof closely approximated the pattern noted for CD90 expression, though 
CD90
diffuse 
pattern continued to be seen in the majority of scars between 90–180 days, 
suggesting that CD90 expression may be retained longer than SMA expression in 
physiologic scarring. Loss of SMA expression and a CD90
diffuse 
pattern coincided with 
reversion to a CD34 positive state (Figure 21). 
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Figure 20. Age based expression of SMA in reparative scars Like CD90 and CD34, 
the presence of SMA expressing myofibroblasts in reparative scars is time dependent. 
SMA expression is focal to absent in scars older than 90 days. The SMA expression 
timeline resembles that of CD90. There was a statistically significant association between 
scar age and SMA expression pattern (p <0.0001) 
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Figure 21.  Relative time course for appearance/disappearance of CD90, CD34 and 
SMA in reparative scars All scars are diffusely CD90 positive until 90 days, after 
which CD90 expression decreases and is absent in scars older than 160–180 days. SMA 
positivity closely resembles CD90 expression, although decrease in SMA expression 
begins earlier that CD90. The loss of a diffuse CD90 expression pattern and SMA 
positivity corresponds to the re-expression of CD34 (reversion)  
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5.8 Many hypertrophic scars are characterized by persistence of SMA+ 
myofibroblasts  
 
 When the relationship between SMA expression and (available) scar age was examined for 
in hypertrophic scars, 9 of the 12 scars (75%) older than 180 days still contained SMA+ 
myofibroblasts and 6 displayed diffuse positivity. Compared with reparative scars, 
hypertrophic scars appear to be characterized by a persistence of SMA+ myofibroblasts. 
Though the gaps in scar-age data for hypertrophic scars preclude comprehensive 
delineation of an SMA expression pattern time-line, it is interesting to note, that the 3 dated 
hypertrophic scars which had lost their SMA expression were all older than 500 days. 
These data suggest that SMA expression, while prolonged is not necessarily permanent, 
though a marked delay in its disappearance may characterize this scar type. 
 
5.8 In keloids, diffuse SMA expression is associated with a hypertrophic scar-like 
architecture 
 
When the presence and fibroblast expression pattern of SMA was examined in keloids, a 
clear dichotomy was present with 60% (n=18) exhibiting a SMA
negative/minority
 pattern and 
40% (n=12) diffusely expressing SMA. Taken into account the conflicting data in the 
literature regarding myofibroblast presence in keloids, a predictor for variations in SMA 
expression patterns was sought. Of the 12 keloidal scars with a SMA
diffuse
 phenotype, 10 
(83.33%) exhibited a hypertrophic scar-like architecture (Figure 22). Additionally, 90.9% 
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(10/11) keloids with a hypertrophic scar-like architecture exhibited diffuse SMA 
expression. Unsurprisingly, there was a statistically significant association between SMA 
expression pattern and keloidal architecture (p<0.0001). 
 
 
Figure 22. SMA expression pattern based on keloidal architecture 
A SMA
diffuse
 expression pattern occurred much more commonly in keloids with a 
hypertrophic scar-like architecture (91 %, n=10), but was only rarely seen in cases with 
the typical expansile architecture (11%, n=2). Keloid architecture was significantly 
associated with SMA expression pattern (p<0.0001) 
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5.9 In reparative, hypertrophic and keloidal scars, CD90
+
 fibroblasts contribute 
more cells to the main scar body compared with classical SMA
+
 myofibroblasts 
 
In order to assess the relative contribution to the scar of CD90+ fibroblasts and SMA
+
 
classical myofibroblasts, all scars expressing both markers were evaluated (n=88). Of 
these, 94.3% (n=83) demonstrated scars with CD90
+ 
fibroblasts predominating over SMA
+
 
myofibroblasts. Three cases (5.7%) demonstrated an approximately equal proportion. No 
scar demonstrated SMA
+
 myofibroblast predominance. These findings suggest that in 
many scars, the bulk of scar fibroblasts are CD90
+
 with a less prominent component of 
classical SMA
+
 fibroblasts (Figures 23, 24 part-1 & 25).  
 
5.10 SMA
+
 myofibroblasts exclusively co-localize to CD90
+
 fibroblast rich areas, 
while CD90
+
 fibroblasts are not limited to SMA
+
 myofibroblasts rich areas 
 
In addition to relative contributions by area positive, the spatial relationship between 
fibroblasts expressing both markers was evaluated. Specifically, we wished to address 
whether SMA
+
 myofibroblasts exist in a spatially independent manner within scars or 
alternatively are exclusively zonally co-localized with CD90 expressing fibroblast-rich 
areas. Eighty-seven (98.9%) of specimens containing any myofibroblasts, demonstrated 
classical SMA
+
 myofibroblasts exclusively within to CD90
+
 fibroblast-rich areas (Figures 
23 & 24 part-1). A single hypertrophic scar demonstrated a tiny isolated focus of 
myofibroblastic differentiation immediately adjacent to a CD90
+
 fibroblast-rich area. 
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CD90 expression typically involved the entire scar and occurred independently of SMA 
expression. These findings appear to suggest that while CD90 expression occurs in the 
absence of SMA expression, expression of SMA may be dependent on CD90 expression.  
 
5.11 SMA
+
 myofibroblasts extensively co-express CD90 
 
Twenty-six specimens (8 reparative, 7 hypertrophic and 11 keloidal scars) were double-
stained with CD90/SMA to accurately assess for dual expressing cells. All samples 
exhibited extensive dual CD90/SMA positivity. Grossly, the vast majority of SMA
+
 
myofibroblasts co-expressed CD90 (Figures 23-D & 24 part-1-D). The pattern of overlap 
was often distinctive, with SMA exhibiting a membranous pattern, forming a rim around 
CD90
+
 cells, which exhibit both a membranous and cytoplasmic pattern. Taken together 
with the delimited overlap of SMA rich zones to CD90 rich zones, and the 
overwhelmingly greater prevalence of CD90
+
 fibroblasts in the scar, these findings are 
compatible with the hypothesis that CD90 expression is associated with myofibroblastic 
differentiation. The copious dual positivity also raises the possibility that myofibroblasts 
are derived from a subset population of CD90
+ 
fibroblasts and if this is so, perhaps 
ultimately are derived from the resident CD34
+ 
fibroblastic cell network. 
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Figure 23. Relative contributions to reparative scar mass and spatial relationship of 
CD90 expressing fibroblasts and SMA
+
 myofibroblasts In 94.3% of all myofibroblast 
containing scars, CD90
+ 
fibroblasts predominated over classical SMA
+
 myofibroblasts 
(A–C) including those with a SMAdiffuse pattern (A, B). Additionally, SMA rich areas are 
contained within CD90 rich areas, but CD90 expression is independent of SMA (A–C). 
Note extensive CD90 expression of SMA
+ 
myofibroblasts, with SMA exhibiting a 
membranous pattern, rimming CD90
+
 cells (D, arrows). Original magnification A, B 
X20; B inset, C X40; D X200
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5.12 In cutaneous scars CD90
+
 fibroblasts contribute to scar collagenization more 
extensively and independently of SMA+ myofibroblasts 
 
In order to ascertain whether CD90
+
 fibroblasts are biologically active with regards to 
ECM/collagen production, 26 scars were stained for procollagen-1(PC-1) expression. 
Eighteen of these were dual stained with CD90 and 8 with SMA. For relative spatial 
comparison, PC-1/CD90 specimens were compared with their previously performed SMA 
stained counterpart and likewise, PC-1/SMA specimens were compared with tissue 
previously stained with CD90. All specimens demonstrated PC-1 expression spatially 
matched to CD90 fibroblast rich areas. In CD90/PC-1 double-stained tissue, extensive co-
expression was visualized confirming that CD90 cells are actively involved in collagen 
production. While PC-1 expression was seen in SMA rich areas, it was never limited to 
these areas, extending beyond these zones and when compared with the corresponding 
CD90 stain, in all cases, PC-1 expression co-localized with CD90 rich zones (Figures 24 
part-2 & 25). In all SMA/PC-1 double-stained tissue, dual marker expression was easily 
identified consistent with the previously widely accepted significant collagen synthesizing 
function of myofibroblasts. Nevertheless, in all samples examined, the CD90
+
 fibroblast 
rather than the SMA
+
 myofibroblast was the major contributor (by area) to scar 
collagenization, doing so independently of SMA expression. 
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Figure 24 Part-1. Comparison of CD90 rich and SMA rich areas in a reparative scar 
In this vertically oriented scar, CD90
 
is expressed diffusely throughout the scar (B) 
predominating over SMA rich areas (C, boxed). SMA
+
 areas are contained within CD90 
rich zones (C, D) and typical extensive co-expression of CD90 is noted ( D, arrows). 
Original magnification A–C X20; D X200 
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Figure 24 Part-2. Relative contribution of CD90
+
 vs. SMA
+
 fibroblasts to scar 
collagenization Staining with procollagen I (PC-1, blue) and CD90 (brown) (1A–C) 
shows diffuse PC-1 positivity in the scar (1A, B), spatially corresponding with CD90 rich 
zones (Figure 24 part 1, panel B) and marked dual positivity with CD90 (1C). PC-1 
(brown) and SMA (blue) (2A–C) staining demonstrates collagen synthesis in SMA rich 
areas (2B) but also extensively in zones without identifiable myofibroblasts (2C), but 
which co-localize with CD90 rich areas (Figure 24 Part-1, panel B). Original 
magnification 1A, 2A X20; 1B, 2B X100; 1C x200; 2C x 40
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Figure 25. CD90
+
/SMA
-
 fibroblasts contribute more to reparative scar 
collagenization than do classical SMA+ myofibroblasts 
Note diffuse CD90 positivity (A) and only focal SMA positivity (B). There is diffuse 
procollagen I (PC-1) positivity corresponding to a CD90 rich distribution (C). Note 
CD90
+
 cells from a SMA poor zone (B, boxed) synthesizing collagen as indicated by co-
expression of PC-1. Original magnification A–C X40; D X200  
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CHAPTER 6 DISCUSSION 
 
Fibroblast biology is a rapidly expanding field in medicine. It is estimated that 45% of 
deaths in the United States are associated with fibrotic disorders (Wynn, 2004). 
Furthermore, no consistently effective anti-fibrotic therapy currently exists and therefore 
further understanding of the mechanisms of fibrosis is of tremendous importance to 
improving survival and quality of human life. The skin provides an easily accessible tissue 
for evaluating fibrosis with well-defined fibrotic states and although findings in one organ 
system are not necessarily generalizable to other systems, any information expanding our 
current grasp of these complex states increases the chance of developing effective 
therapeutic and reversal modalities. This research aimed to help define scar fibroblast 
phenotypes and protein expression patterns in reparative, hypertrophic and keloidal scars. 
 
Based on existing literature demonstrating a profibrotic role for CD90
+
 fibroblasts in 
different tissues and evidence suggesting they may originate from the background CD34
+
 
fibroblastic stromal cell network, a hypothetical model for cutaneous scarring was 
developed. This model proposes that after wounding, resident fibroblastic stromal cells 
lose their CD34 positivity and begin to express CD90, transitioning from quiescence to 
active wound healing fibroblasts. Some of these fibroblasts go on to influence the 
development of classical SMA
+
 myofibroblasts or themselves undergo myofibroblastic 
transition. As wounds heal and ECM homeostasis ensues, active fibroblasts re-transition to 
dormancy, losing their CD90 positivity and reverting to CD34 positive state. A model for 
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pathologic scarring suggests that for various reasons, scar fibroblast remain in an active 
state and are unable to regain or have delayed reversion to their pre-wound CD34+ state. 
The findings of this study support the plausibility of these models. 
 
As shown in the results, active scars are characterized by a CD90
diffuse
/ CD34
negative/minority
 
phenotype with variable SMA positivity. This was observed in reparative scars as well as 
in both categories of pathologic scars. In conjunction with their role as cellular 
components of the scar mass, CD90
+
 fibroblasts are also integrally involved in scar 
collagenization across scar categories, as evidenced by extensive co-expression of PC-1 
(procollagen-I). The utilized anti-PC-1 antibody recognizes the N-terminal of procollagen 
(type I collagen precursor peptide) which is present in cells actively producing collagen 
but is cleaved prior to assembly of mature cross-linked collagen (Bateman, Boot-
Handford, & Lamandé, 2009; Krustrup, Rossen, & Thomsen, 2006). In the skin positivity 
is generally limited to fibroblasts and is therefore used as supplemental marker of 
fibroblastic lineage (Krustrup et al., 2006).   
 
The repeatedly observed CD90
diffuse
/CD34
negative/minority
 phenotype underscores the 
apparent expression reciprocity between CD90 and CD34, with polar differentiated 
fibroblasts within scars expressing one in exchange for the other. Dual expression is 
however observed primarily at the active scar interface with surrounding uninvolved 
dermis or in old scars reverting to their pre-injury CD34
diffuse
/CD90
negative
 phenotype. 
These double-positive cells are interpreted as being in a transitional state of differentiation 
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between latency and activation and were observed in the vast majority of reparative and 
pathologic scars. The idea of scar fibroblasts originating from a local mesenchymal 
progenitor pool has already been discussed in the literature review, and these findings 
further support the existence of such a process in skin biology/pathology. Given the 
existence of these transitional cells, while other sources of fibroblasts including circulating 
fibrocytes and fibroblastic transformation of either epithelial or endothelial cells likely 
play some role in wound healing, we suggest that the ubiquitous dermal fibroblastic 
CD34
+ 
stromal cell network containing a large supply of potential wound-healing 
fibroblasts is, by local proximity and quantity alone, a more likely candidate for the 
primary source of scar fibroblasts. Moreover, the predominantly scar-periphery location of 
these co-expressing cells favors a local transition theory, as no easily explainable reason 
exists why fibrocytes (also exhibiting CD34) arriving from the circulation would almost 
exclusively congregate at the scar-normal interface. An additional observation lending 
support to a local transition theory, is the speed of phenotype transition with extensive 
pan-dermal and subcutaneous replacement of the CD34
+
 network by CD90 expression as 
early as 48 hours. Such rapid repopulation in the distribution of the preexisting resident 
stromal network by either circulating fibroblasts of endo/epithelial trans-differentiation 
seems unlikely. Importantly, with the possible exception of newly wounded skin, the 
presence of dual expressing cells can provide evidence supporting the existence of 
transition, but cannot determine the direction of the transition. Therefore, scars expressing 
dual positivity at their margin may be evolving towards either pole, one conversion 
extending fibrosis and the other reverting. Taken together, this study advances the view 
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that local transition from the background CD34
+
 fibroblastic stromal cell network 
(possibly with contributions from other precursors) represents a likely source of active 
scar fibroblasts.  
  
As predicted in our hypothetical model of physiologic/reparative scarring, the 
CD90
diffuse
/CD34
negative/minority 
phenotype is time-limited, and complete scar maturation 
culminates with return of the CD34
diffuse
/CD90
negative
 network, a process we term a 
“CD34-revertant” or simply “revertant” phenotype. In this study, scars were classified as 
(successfully) revertant only when they expressed CD34 in >50%. It is important to note 
that many scars including keloids demonstrated rare or focal CD34 positivity within the 
scar suggesting possible attempted, but unsuccessful (at the time of evaluation) reversion. 
While reversion was seen as early as 98 days, in general, it was observed in all scars older 
than 160 days. Fascinatingly, scars may exhibit two revertant phases. As noted in the 
results, scars between 2 days and as old as 28 days exhibited wide-spread loss of CD34 
and diffuse neo-expression of CD90 in an indiscriminate distribution, involving the deep 
dermis, subcutaneous tissue and even adjacent uninjured skin. This pattern contrasts 
sharply with the well-outlined CD90
+
 fibrosis characterizing older scars. Potentially, the 
excessive cytokine/growth factor storm associated with acute injury induces this 
unselective transition but as scars enter the 1 month period with tighter regulation of 
cytokine release, the redundant CD90 expressing cells which will not contribute to the 
defined scar re-transition to their pre-injury CD34
+
 state. This “early” CD34 reversion is 
followed by scar proliferation, maturation and eventually, late/complete reversion between 
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160–180 days. This data provides convincing evidence of the time-limited and reversible 
nature of the CD90
diffuse
/CD34
negative/minority
 phenotype.  
 
In pathologic scars, we found that a subset of hypertrophic scars greater than 180 days in 
age (predominantly older than one year), still lacked a revertant phenotype and are 
therefore associated with a prolongation of a CD90
diffuse
CD34
negative/minority
 phenotype. In 
fact, based on the aging methodology (see Section 4.1) where scars with non-explicit 
clinical data were assigned their minimum age, underestimation of pathologic scar-age has 
likely occurred, such that the prolongation of diffuse CD90 expression may be even more 
dramatic than is currently apparent. Reversion can however occur in hypertrophic scars, 
and such scars were identified in thus study, accounting for nearly one-third of the 
samples evaluated. While the day age was not known for most of the revertant scars, the 
youngest revertant scar was age 280 days. Interestingly many of these CD34-revertant 
scars continued to express CD90, unlike their reparative scar counterparts, and could 
additionally, retain their collagen synthesizing function (Figure 18, inset). This 
disconnect in simultaneous and bilateral CD90/CD34 reversion, highlights the aberrant 
prolongation of CD90 expression in this scar type. The observation of four 
CD90
negative/minority
 revertant hypertrophic scars does however suggest that bilateral 
reversion can occur, though the timeline is currently undetermined.  It is unclear what 
factors account for this reversion heterogeneity in hypertrophic scars, allowing for some 
scars to re-enter a physiologic track and eventually regress while others display a non-
revertant, active phenotype extremely late into their lifespan (observed up until 1098 days 
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in this series). Eleven of 12 keloids for which an age was calculable were 300 days or 
older and all exhibited a non-revertant CD90
diffuse
CD34
negative/minority
 phenotype. Keloids 
appear to be characterized by a lack of tendency for reversion and prolongation of an 
active phenotype. The exact mechanism by which a prolongation of a 
CD90
diffuse
CD34
negative/minority
 contributes to the clincopathologic features of hypertrophic 
scars and keloids is unknown. Possibly the observed prolongation of CD90 expression 
represents a failure of its physiologic functioning as it relates to self-regulation. As 
discussed before, CD90 signaling in dermal fibroblasts regulates fibroblast growth and 
increases fibroblast apoptosis preventing excessive fibroblast proliferation.(Schmidt et al., 
2015) It is plausible that failure in this self-regulating apoptotic pathway leads to 
unregulated fibroblast activity characteristic of pathologic scarring. Compatible with this 
theory is the various mechanisms of resistance to apoptosis described in both hypertrophic 
scars and keloids (Linge et al., 2005; Lu et al., 2007; Saed et al., 1998). As detailed 
previously, CD90 expression is also associated with increased active TGF-β levels and 
collagen production (Koumas et al., 2003; Schmidt et al., 2015).  Failure therefore of 
CD90-related apoptosis in the presence of an intact TGF-β release pathway, could result in 
its protracted and excessive release, accounting for the TGF-β hyper-elevation reported in 
keloids and hypertrophic scars (Bettinger et al., 1996; Wang et al., 2000.). Furthermore, as 
demonstrated, these fibroblasts are actively involved in collagen synthesis so that the 
existence of unremitting CD90
 
expression would likely over-collagenize scars. It is thus 
possible, that the exuberant collagen production seen in pathologic scarring may be an 
indirect consequence of failed apoptosis and aberrant cell-longevity rather than a primary 
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intrinsic propensity of pathologic scar fibroblasts to over-produce the ECM. Conceivably, 
via an unknown mechanism, hypertrophic scars are able to overcome this hypothetical 
failure and regain their physiologic trajectory albeit in a delayed fashion. Conversely, 
failure to re-enter a physiologic track may lead to an ancient but active hypertrophic scar 
or an infiltrative keloid. An alternative hypothesis is that aberrations in one or multiple 
profibrotic cellular/molecular pathways may exist and extended CD90 positivity is 
protective in an effort to induce apoptosis and fibroblast differentiation, with similar 
resultant hyper-collagenization as a side-effect of persistent expression. As proof these 
concepts is beyond the scope of this work, additional studies are needed to test these 
hypotheses. 
 
The final goal of this work was to examine the relationship between classical SMA
+
 
myofibroblasts and CD90
+
 fibroblasts. As detailed previously, the presence of 
myofibroblasts in fibrosing conditions is well accepted and these cells have been 
purported as the main effector cell in fibrosis. While somewhat iconoclastic, this study 
finds that though myofibroblasts are significant producers of collagen and are present to 
varying degrees in all scar types, they were never more plentiful than CD90
+
 fibroblasts, 
contributing less cellular mass and new collagen to the scar than their CD90
+
 counterparts. 
Indeed, collagen production, as implied by PC-1 positivity was never limited to SMA+ 
areas but always extended to co-localize with CD90 rich areas. Additionally, SMA 
positivity was, except in one case, limited to areas of CD90 positivity and the majority of 
these myofibroblasts also dually expressed CD90. Again, these findings are consistent 
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with an upstream role of CD90 in the myofibroblastic differentiation pathway. The 
exuberant CD90/SMA positivity further raises the possibility that myofibroblasts are 
directly derived from a subset of CD90
+ 
fibroblasts. Ultimately, if SMA expressing 
fibroblasts are derived from the CD90
+
 fibroblasts, then myofibroblasts are also 
potentially derived from the background CD34
+ 
stromal cell network. Whether or not the 
observed CD90
+
 fibroblasts represent what have been previously described as 
protomyfibroblasts, remains to be seen, but if in fact they are these cells, myofibroblast 
differentiation (as suggested by their name) seems not to be their exclusive or predominant 
role as the majority do not progress to a fully evolved phenotype (Falke, Gholizadeh, 
Goldschmeding, Kok, & Nguyen, 2015; McAnulty, 2007; Otranto et al., 2012; Tomasek et 
al., 2002). While SMA
+ 
myofibroblasts likely play a significant role in profibrotic disease, 
this role may be shared with other fibroblasts and may in actuality, be dependent on them.   
 
One area however in which classical myofibroblasts are unparalleled in their contribution 
is scar contractility. In the current study, though myofibroblasts were present in all scar 
types, diffuse SMA expression was clustered with well contracted scar types i.e. reparative 
scars, hypertrophic scars (with their well-defined hyper-contracted nodules and fascicles) 
and in keloids with a hypertrophic scar-like (non-infiltrative) architecture. Perhaps those 
cases classified as keloid based on the extensive keloidal collagen component but with a 
relatively well defined nodular architecture (suggestive of functional myofibroblastic 
contractile ability) may exhibit clinical features more similar to hypertrophic scars (with 
regards to their tendency to continuously expand far beyond the index scar-line), though 
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studies with stronger clincopathologic correlation are needed to confirm this suggestion. 
The converse seems to be histologically accurate however, with the vast majority of 
keloids displaying a SMA
negative/minority
 phenotype exhibiting large sizes and infiltrative 
borders presumably related to a lack of myofibroblastic contractile ability. As a whole, 
myofibroblasts along with CD90 fibroblasts are significant contributors to scar physiology 
and pathology. 
 
Finally, the evolving evidence for the role of CD90 in fibroblast proliferation, control of 
apoptosis, TGF-β regulation, myofibroblast differentiation and scar collagenization, 
suggests this molecule as a potential therapeutic target for the management of cutaneous 
fibrosis. Therapies decreasing its expression or inducing its reversal to a quiescent state 
may provide an efficacious weapon against these potentially devastating and commonly 
treatment-resistant diseases.  
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CHAPTER 7 STUDY LIMITATIONS 
 
7.1 Study limitations 
 
Retrospective immunohistochemistry based experiments are always limited by the 
inability to see a single specimen as it progresses through its physiology/pathology, with a 
positive/negative finding representing only a snapshot in time of one particular scar, 
giving little indication of what the result might have been a short time before or after 
tissue harvesting. As such, definitive proof that a specific scar type always or never 
exhibits a particular phenotype cannot be achieved via this method. Nevertheless, the 
findings presented provide valuable evidence on the way to definitive proof.   
While overall, the number of specimens evaluated was adequate, it was difficult to collect 
large numbers of scars at a specific age interval to strengthen the generalizability of the 
timelines for reversion. Additionally, information regarding the exact age of many 
pathologic scars was unavailable, preventing further analysis of this data.  
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CHAPTER 8 CONCLUSION 
 
In summary, this study has examined fibroblast phenotypes with regards to the 
relationship between expression of CD90, SMA and CD34 in simple reparative scars, 
hypertrophic scars and keloids. The results define a common 
CD90
diffuse
/CD34
negative/minority 
phenotype as the most common in active scars of all types. 
The findings also show that this expression pattern is transient in physiologic scars and 
that pathologic scars are defined to various degrees by its persistence. This study also 
provides additional evidence to build on the pre-exiting theory that CD90 expressing scar 
fibroblasts are derived from the resident CD34
+
 fibroblastic stromal cell network. It shows 
that CD90
+ 
fibroblasts are active participants in ECM production as it relates to laying 
down of collagen. Additionally investigated was the relationship and relative contributions 
of CD90
+ 
fibroblasts and myofibroblasts with the results suggesting that CD90
+
 fibroblasts 
may contribute more to collagen production and scar mass than do classical 
myofibroblasts. Myofibroblasts however appear to retain their preeminent role in scar 
contracture.  
 
Overall, the findings presented in this study help to define a fibroblast phenotype in 
cutaneous scarring and adds to the existing scientific data regarding local fibroblast 
transitions and the relative roles of various fibroblasts in the genesis of a physiologic or 
pathologic scar.
  
83 
BIBLIOGRAPHY 
 
Armour, A., Scott, P. G., & Tredget, E. E. (2007). Cellular and molecular pathology of 
HTS: Basis for treatment. Wound Repair and Regeneration, 15(Suppl. 1). 
https://doi.org/10.1111/j.1524-475X.2007.00219.x 
Ashcroft, K. J., Syed, F., & Bayat, A. (2013). Site-Specific Keloid Fibroblasts Alter the 
Behaviour of Normal Skin and Normal Scar Fibroblasts through Paracrine 
Signalling. PLoS One, 8(12). https://doi.org/10.1371/journal.pone.0075600 
Atiyeh, B. S., Costagliola, M., & Hayek, S. N. (2005). Keloid or hypertrophic scar: the 
controversy: review of the literature. Annals of Plastic Surgery, 54(6), 676–680. 
https://doi.org/10.1097/01.sap.0000164538.72375.93 
Badid, C., Mounier, N., Costa, A. M., & Desmoulière, A. (2000). Role of myofibroblasts 
during normal tissue repair and excessive scarring: interest of their assessment in 
nephropathies. Histology and Histopathology, 15(1), 269–280. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10668216 
Bailey, A. J., Bazin, S., Sims, T. J., Le Lous, M., Nicoletis, C., & Delaunay, A. (1975). 
Characterization of the collagen of human hypertrophic and normal scars. 
Biochimica et Biophysica Acta - Protein Structure, 405(2), 412–421. 
https://doi.org/10.1016/0005-2795(75)90106-3 
Barrientos, S., Stojadinovic, O., Golinko, M. S., Brem, H., & Tomic-Canic, M. (2008). 
Growth factors and cytokines in wound healing. Wound Repair and Regeneration, 
16(5), 585–601. https://doi.org/10.1111/j.1524-475X.2008.00410.x 
 
  
84 
Bateman, J. F., Boot-Handford, R. P., & Lamandé, S. R. (2009). Genetic diseases of 
connective tissues: cellular and extracellular effects of ECM mutations. Nature 
Reviews. Genetics, 10(3), 173–183. https://doi.org/10.1038/nrg2520 
Bettinger, D. A., Yager, D. R., Diegelmann, R. F., & Cohen, I. K. (1996). The effect of 
TGF-beta on keloid fibroblast proliferation and collagen synthesis. Plastic and 
Reconstructive Surgery, 98(5), 827–833. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8823022 
Biernacka, A., Dobaczewski, M., & Frangogiannis, N. G. (2011). TGF-β signaling in 
fibrosis. Growth Factors, 29(5), 196–202. 
https://doi.org/10.3109/08977194.2011.595714 
Brandau, S., Bruderek, K., Hestermann, K., Görtz, G.-E., Horstmann, M., Mattheis, S., 
… Berchner-Pfannschmidt, U. (2015). Orbital Fibroblasts From Graves’ 
Orbitopathy Patients Share Functional and Immunophenotypic Properties With 
Mesenchymal Stem/Stromal Cells. Investigative Ophthalmology & Visual Science, 
56(11), 6549. https://doi.org/10.1167/iovs.15-16610 
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994). Circulating 
fibrocytes define a new leukocyte subpopulation that mediates tissue repair. 
Molecular Medicine, 1(1), 71–81. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8790603 
Ceafalan, L., Gherghiceanu, M., Popescu, L. M., & Simionescu, O. (2012). Telocytes in 
human skin--are they involved in skin regeneration? Journal of Cellular and 
Molecular Medicine, 16(7), 1405–1420. https://doi.org/10.1111/j.1582-
  
85 
4934.2012.01580.x 
Childs, D. R., & Murthy, A. S. (2017). Overview of Wound Healing and Management. 
Surgical Clinics of North America. https://doi.org/10.1016/j.suc.2016.08.013 
Darby, I. A., & Hewitson, T. D. (2007). Fibroblast differentiation in wound healing and 
fibrosis. International Review of Cytology, 257, 143–179. 
https://doi.org/10.1016/S0074-7696(07)57004-X 
Darby, I., Skalli, O., & Gabbiani, G. (1990). Alpha-smooth muscle actin is transiently 
expressed by myofibroblasts during experimental wound healing. Laboratory 
Investigation, 63(1), 21–29. https://doi.org/10.1017/CBO9781107415324.004 
Díaz-Flores, L., Gutiérrez, R., García, M. P., González, M., Sáez, F. J., Aparicio, F., … 
Madrid, J. F. (2015). Human resident CD34+ stromal cells/telocytes have progenitor 
capacity and are a source of αSMA+ cells during repair. Histology and 
Histopathology, 30(5), 615–627. https://doi.org/10.14670/HH-30.615 
Díaz-Flores, L., Gutiérrez, R., García, M. P., Sáez, F. J., Díaz-Flores, L., Valladares, F., 
& Madrid, J. F. (2014). CD34+ stromal cells/fibroblasts/fibrocytes/telocytes as a 
tissue reserve and a principal source of mesenchymal cells. Location, morphology, 
function and role in pathology. Histology and Histopathology, 29(7), 831–870. 
https://doi.org/10.14670/HH-29.831 
Ehrlich, H. P., Desmoulière, A., Diegelmann, R. F., Cohen, I. K., Compton, C. C., 
Garner, W. L., … Gabbiani, G. (1994). Morphological and immunochemical 
differences between keloid and hypertrophic scar. The American Journal of 
Pathology, 145(1), 105–113. Retrieved from 
  
86 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1887298&tool=pmcentr
ez&rendertype=abstract 
Falke, L. L., Gholizadeh, S., Goldschmeding, R., Kok, R. J., & Nguyen, T. Q. (2015). 
Diverse origins of the myofibroblast—implications for kidney fibrosis. Nature 
Reviews. Nephrology, 11(4), 233–244. https://doi.org/10.1038/nrneph.2014.246 
Finnson, K. W., Arany, P. R., & Philip, A. (2013). Transforming Growth Factor Beta 
Signaling in Cutaneous Wound Healing: Lessons Learned from Animal Studies. 
Advances in Wound Care, 2(5), 225–237. https://doi.org/10.1089/wound.2012.0419 
Finnson, K. W., McLean, S., Di Guglielmo, G. M., & Philip, A. (2013). Dynamics of 
Transforming Growth Factor Beta Signaling in Wound Healing and Scarring. 
Advances in Wound Care, 2(5), 195–214. https://doi.org/10.1089/wound.2013.0429 
Fujiwara, M., Muragaki, Y., & Ooshima, A. (2005). Upregulation of transforming growth 
factor-β1 and vascular endothelial growth factor in cultured keloid fibroblasts: 
relevance to angiogenic activity. Archives of Dermatological Research, 297(4), 161–
169. https://doi.org/10.1007/s00403-005-0596-2 
Furtado, M. B., Costa, M. W., & Rosenthal, N. A. (2016). The cardiac fibroblast: Origin, 
identity and role in homeostasis and disease. Differentiation, 92(3), 93–101. 
https://doi.org/10.1016/j.diff.2016.06.004 
Gabbiani, G. (2003). The myofibroblast in wound healing and fibrocontractive diseases. 
The Journal of Pathology, 200(4), 500–503. https://doi.org/10.1002/path.1427 
Goldman, R. (2004). Growth factors and chronic wound healing: past, present, and 
future. Advances in Skin and Wound Care, 17(1), 24–35. 
  
87 
https://doi.org/10.1097/00129334-200401000-00012 
Gurtner, G., Werner, S., Barrandon, Y., & Longaker, M. (2008). Wound repair and 
regeneration. Nature, 453(7193), 314–321. https://doi.org/10.1038/nature07039 
Hagood, J. S., Prabhakaran, P., Kumbla, P., Salazar, L., MacEwen, M. W., Barker, T. H., 
… Selman, M. (2005). Loss of fibroblast Thy-1 expression correlates with lung 
fibrogenesis. The American Journal of Pathology, 167(2), 365–379. 
https://doi.org/10.1016/S0002-9440(10)62982-3 
Hinz, B. (2007). Formation and function of the myofibroblast during tissue repair. The 
Journal of Investigative Dermatology, 127(3), 526–537. 
https://doi.org/10.1038/sj.jid.5700613 
Hinz, B. (2010). The myofibroblast: Paradigm for a mechanically active cell. Journal of 
Biomechanics, 43(1), 146–155. https://doi.org/10.1016/j.jbiomech.2009.09.020 
Hinz, B., Phan, S. H., Thannickal, V. J., Galli, A., Bochaton-Piallat, M.-L., & Gabbiani, 
G. (2007). The Myofibroblast. The American Journal of Pathology, 170(6), 1807–
1816. https://doi.org/10.2353/ajpath.2007.070112 
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., … 
Gabbiani, G. (2012). Recent developments in myofibroblast biology: paradigms for 
connective tissue remodeling. The American Journal of Pathology, 180(4), 1340–
1355. https://doi.org/10.1016/j.ajpath.2012.02.004 
Huang, C; Akashai, S; Hyakusoku, H; Ogawa, R. (2014). Are keloid and hypertrophic 
scar different forms of the same disorder? A fibroproliferative skin disorder 
hypothesis based on keloid findings. International Wound Journal, 11(5), 517–522. 
  
88 
https://doi.org/10.1111/j.1742-481X.2012.01118.x 
Hudon-David, F., Bouzeghrane, F., Couture, P., & Thibault, G. (2007). Thy-1 expression 
by cardiac fibroblasts: lack of association with myofibroblast contractile markers. 
Journal of Molecular and Cellular Cardiology, 42(5), 991–1000. 
https://doi.org/10.1016/j.yjmcc.2007.02.009 
Humphreys, B. D., Lin, S.-L., Kobayashi, A., Hudson, T. E., Nowlin, B. T., Bonventre, J. 
V., … Duffield, J. S. (2010). Fate Tracing Reveals the Pericyte and Not Epithelial 
Origin of Myofibroblasts in Kidney Fibrosis. The American Journal of Pathology, 
176(1), 85–97. https://doi.org/10.2353/ajpath.2010.090517 
Imaizumi, R., Akasaka, Y., Inomata, N., Okada, E., Ito, K., Ishikawa, Y., & Maruyama, 
Y. (2009). Promoted activation of matrix metalloproteinase (MMP)-2 in keloid 
fibroblasts and increased expression of MMP-2 in collagen bundle regions: 
implications for mechanisms of keloid progression. Histopathology, 54(6), 722–730. 
https://doi.org/10.1111/j.1365-2559.2009.03287.x 
Iwaisako, K., Brenner, D. A., & Kisseleva, T. (2012). What’s new in liver fibrosis? The 
origin of myofibroblasts in liver fibrosis. Journal of Gastroenterology and 
Hepatology, 27(Suppl. 2), 65–68. https://doi.org/10.1111/j.1440-1746.2011.07002.x 
Jfri, A., Rajeh, N., & Karkashan, E. (2015). A Case of Multiple Spontaneous Keloid 
Scars. Case Reports in Dermatology, 7(2), 156–160. 
https://doi.org/10.1159/000437249 
Kelly, A. P. (1988). Keloids. Dermatologic Clinics, 6(3), 413–424. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/3048824 
  
89 
Kis, K., Liu, X., & Hagood, J. S. (2011). Myofibroblast differentiation and survival in 
fibrotic disease. Expert Reviews in Molecular Medicine, 13, e27. 
https://doi.org/10.1017/S1462399411001967 
Kischer, C. W., Wagner, H. N., Pindur, J., Holubec, H., Jones, M., Ulreich, J. B., & 
Scuderi, P. (1989). Increased fibronectin production by cell lines from hypertrophic 
scar and keloid. Connective Tissue Research, 23(4), 279–288. 
https://doi.org/10.3109/03008208909005627 
Köse, O., & Waseem, A. (2008). Keloids and hypertrophic scars: Are they two different 
sides of the same coin? Dermatologic Surgery. https://doi.org/10.1111/j.1524-
4725.2007.34067.x 
Koumas, L., King, A. E., Critchley, H. O., Kelly, R. W., & Phipps, R. P. (2001). 
Fibroblast heterogeneity: existence of functionally distinct Thy 1(+) and Thy 1(-) 
human female reproductive tract fibroblasts. The American Journal of Pathology, 
159(3), 925–935. https://doi.org/10.1016/S0002-9440(10)61768-3 
Koumas, L., Smith, T. J., Feldon, S., Blumberg, N., & Phipps, R. P. (2003). Thy-1 
expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic 
phenotypes. The American Journal of Pathology, 163(4), 1291–1300. 
https://doi.org/10.1016/S0002-9440(10)63488-8 
Krustrup, D., Rossen, K., & Thomsen, H. K. (2006). Procollagen 1 - a marker of 
fibroblastic and fibrohistiocytic skin tumors. Journal of Cutaneous Pathology, 33(9), 
614–618. https://doi.org/10.1111/j.1600-0560.2006.00484.x 
 
  
90 
Kuwahara, H., Tosa, M., Egawa, S., Murakami, M., Mohammad, G., & Ogawa, R. 
(2016). Examination of Epithelial Mesenchymal Transition in Keloid Tissues and 
Possibility of Keloid Therapy Target. Plastic and Reconstructive Surgery - Global 
Open, 4(11), e1138. https://doi.org/10.1097/GOX.0000000000001138 
Lee, Y.S., Vijayasingam, S. (1995). Mast cells and myofibroblasts in keloid: a light 
microscopic, immunohistochemical and ultrastructural study. Annals of the Academy 
of Medicine, Singapore, 24(6), 902–905. 
Lee, D. E., Trowbridge, R. M., Ayoub, N. T., & Agrawal, D. K. (2015). High-mobility 
Group Box Protein-1, Matrix Metalloproteinases, and Vitamin D in Keloids and 
Hypertrophic Scars. Plastic and Reconstructive Surgery - Global Open, 3(6), e425. 
https://doi.org/10.1097/GOX.0000000000000391 
Lee, J. Y.-Y., Yang, C.-C., Chao, S.-C., & Wong, T.-W. (2004). Histopathological 
differential diagnosis of keloid and hypertrophic scar. The American Journal of 
Dermatopathology, 26(5), 379–384. https://doi.org/10.1097/00000372-200410000-
00006 
Lee, T. Y., Chin, G. S., Kim, W. J., Chau, D., Gittes, G. K., & Longaker, M. T. (1999). 
Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Annals 
of Plastic Surgery, 43(2), 179–184. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10454326 
Linge, C., Richardson, J., Vigor, C., Clayton, E., Hardas, B., & Rolfe, K. J. (2005). 
Hypertrophic scar cells fail to undergo a form of apoptosis specific to contractile 
collagen - The role of tissue transglutaminase. Journal of Investigative Dermatology, 
  
91 
125(1), 72–82. https://doi.org/10.1111/j.0022-202X.2005.23771.x 
Lu, F., Gao, J., Ogawa, R., Hyakusoku, H., & Ou, C. (2007). Fas-mediated apoptotic 
signal transduction in keloid and hypertrophic scar. Plastic and Reconstructive 
Surgery, 119(6), 1714–1721. https://doi.org/10.1097/01.prs.0000258851.47193.06 
Manole, C. G., & Simionescu, O. (2016). The Cutaneous Telocytes. Advances in 
Experimental Medicine and Biology, 913, 303–323. https://doi.org/10.1007/978-
981-10-1061-3_20 
Mari, W., Alsabri, S. G., Tabal, N., Younes, S., Sherif, A., & Simman, R. (2016). Novel 
Insights on Understanding of Keloid Scar: Article Review. Journal of the American 
College of Clinical Wound Specialists, 7(1–3), 1–7. 
https://doi.org/10.1016/j.jccw.2016.10.001 
Martins, V., Gonzalez De Los Santos, F., Wu, Z., Capelozzi, V., Phan, S. H., & Liu, T. 
(2015). FIZZ1-Induced Myofibroblast Transdifferentiation from Adipocytes and Its 
Potential Role in Dermal Fibrosis and Lipoatrophy. The American Journal of 
Pathology, 185(10), 2768–2776. https://doi.org/10.1016/j.ajpath.2015.06.005 
McAnulty, R. J. (2007). Fibroblasts and myofibroblasts: Their source, function and role 
in disease. The International Journal of Biochemistry & Cell Biology, 39(4), 666–
671. https://doi.org/10.1016/j.biocel.2006.11.005 
Meng, X.-M., Wang, S., Huang, X.-R., Yang, C., Xiao, J., Zhang, Y., … Lan, H.-Y. 
(2016). Inflammatory macrophages can transdifferentiate into myofibroblasts during 
renal fibrosis. Cell Death and Disease, 7(12), e2495. 
https://doi.org/10.1038/cddis.2016.402 
  
92 
Moulin, V., Larochelle, S., Langlois, C., Thibault, I., Lopez-Vallé, C. A., & Roy, M. 
(2004). Normal Skin Wound and Hypertrophic Scar Myofibroblasts Have 
Differential Responses to Apoptotic Inductors. Journal of Cellular Physiology, 
198(3), 350–358. https://doi.org/10.1002/jcp.10415 
Nazari, B., Rice, L. M., Stifano, G., Barron, A. M. S., Wang, Y. M., Korndorf, T., … 
Browning, J. L. (2016). Altered Dermal Fibroblasts in Systemic Sclerosis Display 
Podoplanin and CD90. American Journal of Pathology, 186(10), 2650–2664. 
https://doi.org/10.1016/j.ajpath.2016.06.020 
Nwomeh, B. C., Liang, H. X., Diegelmann, R. F., Cohen, I. K., & Yager, D. R. (1998). 
Dynamics of the matrix metalloproteinases MMP-1 and MMP-8 in acute open 
human dermal wounds. Wound Repair and Regeneration, 6(2), 127–134. 
https://doi.org/10.1046/j.1524-475X.1998.60206.x 
Otranto, M., Sarrazy, V., Bonté, F., Hinz, B., Gabbiani, G., & Desmouliere, A. (2012). 
The role of the myofibroblast in tumor stroma remodeling. Cell Adhesion & 
Migration, 6(3), 203–219. https://doi.org/10.4161/cam.20377 
Picard, N., Baum, O., Vogetseder, A., Kaissling, B., & Le Hir, M. (2008). Origin of renal 
myofibroblasts in the model of unilateral ureter obstruction in the rat. 
Histochemistry and Cell Biology, 130(1), 141–155. https://doi.org/10.1007/s00418-
008-0433-8 
Rege, T. A., & Hagood, J. S. (2006). Thy-1, a versatile modulator of signaling affecting 
cellular adhesion, proliferation, survival, and cytokine/growth factor responses. 
Biochimica et Biophysica Acta, 1763(10), 991–999. 
  
93 
https://doi.org/10.1016/j.bbamcr.2006.08.008 
Rowlatt, U. (1979). Intrauterine wound healing in a 20 week human fetus. Virchows 
Archiv. A, Pathological Anatomy and Histology, 381(3), 353–361. 
https://doi.org/10.1007/BF00432477 
Saed, G. M., Ladin, D., Olson, J., Han, X., Hou, Z., & Fivenson, D. (1998). Analysis of 
p53 gene mutations in keloids using polymerase chain reaction-based single-strand 
conformational polymorphism and DNA sequencing. Archives of Dermatology, 
134(8), 963–967. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9722726 
Santucci, M., Borgognoni, L., Reali, U. M., & Gabbiani, G. (2001). Keloids and 
hypertrophic scars of Caucasians show distinctive morphologic and 
immunophenotypic profiles. Virchows Archiv, 438(5), 457–463. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11407473 
Sarrazy, V., Billet, F., Micallef, L., Coulomb, B., & Desmoulière, A. (2011). 
Mechanisms of pathological scarring: role of myofibroblasts and current 
developments. Wound Repair and Regeneration, 19(Suppl 1), s10–15. 
https://doi.org/10.1111/j.1524-475X.2011.00708.x 
Schmid, P., Itin, P., Cherry, G., Bi, C., & Cox, D. A. (1998). Enhanced expression of 
transforming growth factor-beta type I and type II receptors in wound granulation 
tissue and hypertrophic scar. The American Journal of Pathology, 152(2), 485–493. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9466575 
Schmidt, M., Gutknecht, D., Simon, J. C., Schulz, J.-N., Eckes, B., Anderegg, U., & 
Saalbach, A. (2015). Controlling the Balance of Fibroblast Proliferation and 
  
94 
Differentiation: Impact of Thy-1. The Journal of Investigative Dermatology, 135(7), 
1893–1902. https://doi.org/10.1038/jid.2015.86 
Slany, A., Meshcheryakova, A., Beer, A., Ankersmit, H., Paulitschke, V., & Gerner, C. 
(2014). Plasticity of fibroblasts demonstrated by tissue-specific and function-related 
proteome profiling. Clinical Proteomics, 11(1), 41. https://doi.org/10.1186/1559-
0275-11-41 
Suarez, E., Syed, F., Alonso-Rasgado, T., & Bayat, A. (2015). Identification of 
biomarkers involved in differential profiling of hypertrophic and keloid scars versus 
normal skin. Archives of Dermatological Research, 307(2), 115–133. 
https://doi.org/10.1007/s00403-014-1512-4 
Ten Dijke, P., & Arthur, H. M. (2007). Extracellular control of TGFβ signalling in 
vascular development and disease. Nature Reviews. Molecular Cell Biology, 8(11), 
857–869. https://doi.org/10.1038/nrm2262 
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002). 
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature 
Reviews. Molecular Cell Biology, 3(5), 349–463. https://doi.org/10.1038/nrm809 
Wang, R., Ghahary, A., Shen, Q., Scott, P. G., Roy, K., & Tredget, E. E. (2000). 
Hypertrophic scar tissues and fibroblasts produce more transforming growth factor-
beta1 mRNA and protein than normal skin and cells. Wound Repair and 
Regeneration, 8(2), 128–137. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10810039 
 
  
95 
Werner, S., Krieg, T., & Smola, H. (2007). Keratinocyte-fibroblast interactions in wound 
healing. The Journal of Investigative Dermatology, 127(5), 998–1008. 
https://doi.org/10.1038/sj.jid.5700786 
Williams, A. F., & Gagnon, J. (1982). Neuronal cell Thy-1 glycoprotein: homology with 
immunoglobulin. Science, 216(4547), 696–703. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/6177036 
Wipff, P. J., & Hinz, B. (2009). Myofibroblasts work best under stress. Journal of 
Bodywork and Movement Therapies, 13(2), 121–127. 
https://doi.org/10.1016/j.jbmt.2008.04.031 
Wynn, T. A. (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Reviews. 
Immunology, 4(8), 583–594. https://doi.org/10.1038/nri1412 
Wynn, T. A. (2008). Cellular and molecular mechanisms of fibrosis. Journal of 
Pathology, 214(2), 199–210. https://doi.org/10.1002/path.2277 
Xia, H., Bodempudi, V., Benyumov, A., Hergert, P., Tank, D., Herrera, J., … Henke, C. 
A. (2014). Identification of a cell-of-origin for fibroblasts comprising the fibrotic 
reticulum in idiopathic pulmonary fibrosis. American Journal of Pathology, 184(5), 
1369–1383. https://doi.org/10.1016/j.ajpath.2014.01.012 
Yuasa, T., Juniantito, V., Ichikawa, C., Yano, R., Izawa, T., Kuwamura, M., & Yamate, 
J. (2013). Thy-1 expression, a possible marker of early myofibroblast development, 
in renal tubulointerstitial fibrosis induced in rats by cisplatin. Experimental and 
Toxicologic Pathology, 65(5), 651–659. https://doi.org/10.1016/j.etp.2012.07.005 
  
96 
CURRICULUM VITAE 
 
 
  
97 
  
98 
 
  
99 
  
100 
 
